annual reportkey figure group sale millions chf cer core operating profit millions chf cer core earning share chf cer operate free cash flow millions chf cer r investment millions chf cer dividend chf cer total shareholder return value chf invest period end dec mar jun sep dec roche gs price roche b price peer set index patient clinical trial patient number employee employee cer constant exchange rate average fullyear propose board director price translate constant chf exchange rate usd eur jpy gbp fulltime equivalent yado leinad nnamleggid dnalor key event roche group roche annual general management change meet shareholder daniel oday head authorise dividend roche diagnostic increase chf appoint new head share nonvoting equity roche pharma roland company th diggelmann assume dividend increase position head year roche diagnostic roche continue streamline latestage pipeline research develop considerable progress ment activity take clini decision close site cal trial deliver positive nutley new jersey usa result underpin respective r activity strength innovation consolidate strategy switzerland germany pharmaceuticals fda approve fda approve perjeta erivedge vismodegib pertuzumab patient firstinclass hedgehog herpositive meta pathway inhibitor static breast cancer new adult advance personalise medicine give basal cell carcinoma patient time disease worsen new datum phase iii second interim emilia study show datum analysis roche trastuzumab daloutcome trial roche emtansine tdm decide discontinue significantly improve survival development dalcetrapib people herpositive medicine low cardio metastatic breast cancer vascular risk roche file approval fda emacorporate sustainability reduce second transnet water consumption phelophepa healthcare greenhouse gas train inaugurate emission south africa roche double track reach support reach fiveyear goal people year improvement efficiency rural south africa train service roche recognise roche name great place work healthcare supersector achieve ranking leader dow jones prestigious award listing sustainability index djsi worldwide fourth consecutive year rank confir mation roche commit ment longterm sustainable value creation diagnostic new guideline recognise fda clear benefit genotype accuchek combo human papillomavirus system roche new inter hpv active insulin pump system principal cause cervical people diabete cancer woman accuchek nano smartview system roche apply science roche launch guideit diabetes care initiate clinical trial involve restructure measure cardiac marker ntprobnp sustain longterm profit guide therapy heart ability failure patientsthe value innovationroche glance roche focus fitting treatment patient innovative medicine diagnostic test global leader innovation sustainable company great workplace roche leader researchfocuse committed sustainability drive share set stan healthcare combine strength run business way dard integrity courage reach pharmaceutical diagnostic ethical responsible create longterm boundary passion value country patient treat employee research centre patient clinical trial manufacture site biotech oncology vitro diagnostic hospital market pharmaceutical diagnostic world large biotech company product global leader vitro diagnostic testing portfolio truly differentiate therapy robust pipeline early detection evaluation monitoring disease investigational new medicine frontrunner management diabete sale therapeutic area cer sale business area cer oncology professional diagnostic virology diabete care inflammationautoimmune transplantation molecular diagnostic metabolismbone apply science ophthalmology tissue diagnostic respiratory disease cardiovascular disease renal anemia central nervous system infectious disease therapeutic area pharmaceutical sale billion chf diagnostic sale billion chf roche group sale billion chf roche topselle product fulltime equivalent fte cer constant exchange rate average fullyear strategic priority patient need strive help patient need truly differ million cancer entiate diagnostic medicine focus lie disease area unmet medical need million hepatitis c oncology inflammation infectious disease metabolism central nervous system million schizophrenia million asthma million diabetes personalise healthcare personalise healthcare roche provide right therapy right group patient personalise right time provide medicine diagnostic pharmaceutical diagnostic healthcare optimise patient care enable tangible improve ment health quality life survival excellence science roche highly innovative healthcare company inhouse cut edge science robust r foundation autono mous research unit partnership optimal resource allocation world foster diversity research translate science medicine external innovation innovative pricing model establish roche aim bring medicine diagnostic market pressure test patient need possible active payer explore innovative pricing model patient access scheme target individual market emerge market buildup healthcare system tight cost parameter stakeholder value discover develop innovative product patient employee aim provide value stakeholder patient doctor employee investor value society stakeholder shareholder providerstopselle pharmaceutical millions chf product mabthera herceptin avastin pegasys xeloda rituxan sale growth cer active substance rituximab trastuzumab bevacizumab peginterferon alfaa capecitabine indication nonhodgkin lymphoma herpositive breast colorectal cancer breast hepatitis b c colorectal cancer chronic lymphocytic cancer advanced cancer nonsmall cell colon cancer leukemia rheumatoid positive stomach cancer lung cancer kidney breast cancer arthritis ancaasso cancer ovarian cancer ciate vasculitis glioblastoma cer constant exchange rate average fullyear topselle diagnostic millions chf accuchek nano smartview cobas e cobas c cobas taqman ventana ihc reagents product accuchek cobas e module cobas c modules cobas ampliprep immunohistochemistry monitoring system modular analytic modular analytic cobas taqman situ hybridisation elecsys cobas integra sale growth cer market segment blood glucose monitoring immunoassay clinical chemistry virology hepatitis b advanced tissue stain hepatitis c hiv business area diabetes care professional diagnostic professional diagnostic molecular diagnostic tissue diagnosticsthe value innovation roche global leader innovation medicine diagnostic testing annual report highlight inno vation bring value patient prescriber healthcare reimbursement society possible new medicine actemraroactemra highsensitivity herpositive meta relief agony childhood cardiac test static breast cancer arthritis precise testing life new generation cancer death decision treatment accurate diagnosis work insurance cobas hpv cintec personalise healthcare industry china test focus healthcare budget improve health insurance well screen cervical target treatment coverage cancer patient cancer special feature fight cancer go mining biotech innovation pharma year cancer research roche r lono cn aoc lvh eae cti oop nne cn mrz e yb ae tir ng g value c olau rs lt dti ic n ha g e al c li ton hnd tu ribst ur ty ion oarifcu racshtscna ekde en gr ia f vy nr em c sc ide ed l csoo uh p rwy e ehn sv oen eaon ae l eat ab r nnts r h ovt sr e c eo dyht j ei ia u eh drt l r p u cl g ls ie eiie n elsn roi st e c e b c nes ro c ch pp u sfdon e ie f fa ilr r ee dd nf ol e oflo f c eei ilem yd mf eip ta r n ff r sfi le f ei tl ts e dgce r uhr de tn botn ue ha w et w l tt e e h clo ti r e etl eyo al nf un b lp uud lbi r n cnut roe sge eur ei hd efe nv vv h l f e e h e ea ge ra kha yrut trs l c ao spn h gi afsu vp ih itt rr tn r ha yot ta soe c h uyu r tb cf coa er gp ace en ct kfat nh e ae lhmc ac rlw taclne ne lf iaa c bb e yr cnd ia ti u n ec gad nc tf trs e r hfu haoc ce ener r r et en r ht e iili ra un oe ris sl ef l insg ni dl ie n e msi bct rnv ld w u ta ede eh rr h sgu ci r e c yy sw tds ho hi ne ir ae di tc l hy fdl ec lho ug cie tsf lher not lpo c os ut aoy dc efi ih u r sm zea ta lis g neeh h enn cke dd dhoe ce fawtc srt codreh er fio ei n reo mt c nc esh c aa h pc e n ut ceew rt nh tm r ese ahi e pts b co n toh tu ire eu os nd eil f lt rm e g le mt ba e wr et ter et rt h u r e nfo de ee n r r dpc ol rl ffu es shr not r ie r uade eb ha tfn cee ueea til opr ng nnee rati epf cce nw n sr ooer n et goa mcn lad rfs nv yt es tnl e bigl et e sy av n sq e r eg ta e u il tnd co e e ha nvp tn pg ie na ho sve n r n r ec ecl od iy oa nc net l tt os se ro rs tfi tn eir ee f v dirt cg arh eev ia ota e e ac mt unrh e g iht na sd e aer e ti gl e e n hr dnpc c vsa te aa yu h st os ynm ttt e c f igo dc e aace ct eo sgn aln et casx nrt sd e ois c n ewuao v ef r ct erc ri e r sa hd er mf twn r abeu uuc gf e ce g bf yei tin hr ys year cancer research roche fight cancer go special feature roche business report rochearoncofeatureengindd content inside cover key figure roche glance key event letter chairman letter ceo management business review group result outlook market environment group strategy research development highlight access external innovation improve rd productivity pharmaceutical pipeline manufacturing procurement pharmaceutical manufacturing quality compliance diagnostic manufacturing procurement marketing distribution tailor market strategy innovative pricing model responsible business code conduct patient safety stakeholder engagement contribute public policy people build great workplace learn career development attract retain talent embrace diversity community involvement humanitarian social project art culture science education community environment safety security health environment improve monitoring performance safeguard employee property minimise environmental footprint pharmaceutical environment corporate governance remuneration report corporate governance remuneration report independent assurance report letter shareholder franz b humer dear shareholder high level public debt especially europe united states continue strength emerge economy dominant influence healthcare sector bringing challenge opportunity overall demand year industry cost pressure market continue increase notwithstanding challenge roche post good result year firm strategy develop medically differentiate medicine diagnostic product disease area high unmet medical need group sale increase constant exchange rate e emerge market nation asia latin america billion swiss franc swiss franc roche record fifth sale cancer cardio pharmaceutical diagnostic division grow fast vascular disease lead cause death respective market roche deliver strong growth emerge economy demand medicine rise united states emerge market whilst result actively expand position asia europe continue feel pricing pressure healthcare latin america improve global access medi budget cut focus highvalue medicine diagnos cine diagnostic product tic test mean relative rest indus try sale europe hold optimise organisational structure past year adapt process change market environ general see increase shift ment notable closure roche site establish market especially europe fast grow nutley new jersey united states conso roche business report letter shareholderslidation research earlystage development activity previously announce prof bruno gehrig lodewijk closing site easy decision nutley play j r de vink member board director pivotal role company success past year decide stand reelection board director annual general meeting core operating profit improve significantly year service exceptionally valuable net income slightly high billion swiss franc contribution growth company owe good operating performance offset cost associ debt gratitude ate number major restructuring programme high tax rate comparable basis core net income board director propose election dr severin previousyear period constant exchange rate schwan ceo roche group new member swiss francs board director roche holding ltd enable board director corporate executive committee highlight year dow jones sustainability work closely help promote index name roche supersector leader fourth con growth company today challenge market environ secutive year rank world sustainable ment healthcare company new corporate executive committee member lead way personalise healthcare announce second half recruit leader personalise healthcare roche uniquely posi company daniel oday chief operating tioned develop treatment raise current standard officer coo diagnostic division appoint coo care extend improve live patient pharmaceutical division effective september project pharmaceutical pipeline devel roland diggelmann head asiapacific region ope conjunction companion diagnostic test roche diagnostic appoint new member strengthen personalise healthcare launch corporate executive committee daniel oday cancer medicine perjeta breast cancer zelboraf successor coo diagnostic division melanoma alongside companion diagnostic newly constitute form corporate executive com medical innovation benefit patient mittee continue progress group current strategic partner healthcare market payer economy course sustainably drive roche success global society general regrettably europe particular leader healthcare clinical differentiation key serving continue focus cost shortterm think patient medical need well safe costeffec ing harbour risk miss longerterm opportuni tive way crucial increasingly cost tie economy society longerterm perspective sensitive environment tends neglect discussion rise health care cost contribution pharmaceutical roche continue advance successful strategy diagnostic medical progress focus innovation benefit patient physician employee shareholder sustainable success apply roche business generally require longterm thinking wardlooke investment innovation continue motor drive longterm success success story continue open dialogue poli tician industry franz b humer board propose swiss francs dividend chairman board view good result board director propos ing dividend increase swiss franc share nonvoting equity security swiss franc half net income distribute shareholder dividend subject approval th divi dend increase year letter shareholder roche business report letter shareholder severin schwan dear shareholder difficult market environment company deliver strong performance continue positive growth trend recent year meet sale earning target importantly significant stride product development new roche cancer medicine approve month new cancer drug file approval expand advance research develop core operating profit increase constant exchange ment like summarise key financial result rate billion swiss franc outpace sale growth significantly group core operating profit margin rise sale pharmaceutical division rise constant percentage point drive mainly productivity exchange rate billion swiss franc swiss gain cost saving franc growth drive cancer medicine herceptin mabtherarituxan avastin zelboraf rheu core earning share key metric underlying business matoid arthritis drug actemraroactemra pegasys hepa performance exclude item global restruc titis c medicine tamiflu ture charge amortisation impairment intangible asset increase constant exchange rate diagnostic division consolidated global market lead original expectation ership sale billion swiss franc swiss franc drive strong demand clinical laborato achieve result like thank employee rie immunoassay sophisticated blood test diagnose hard work commitment professionalism range disease perform continue effort continue roche world suc decadelong trajectory doubledigit growth cessful healthcare company roche business report letter shareholdersbringe innovation patient maximise r productivity development pipeline key foundation roche future operationally restructure pharmaceutical show healthy growth new search development activity order well allocate molecular entity clinical development overall resource improve efficiency result posi tive datum trial drug latestage clinical test difficult decision close roche site nutley new ing strengthen business innovative product jersey result saving site consolidation secure future year come diagnostic pipeline relate infrastructure cost allow reallocate resource remain solid new product launch key market grow number clinical programme whilst main taine stable r expenditure overall aware impact employee affect significant highlight extension roche closure family provide affected product portfolio treat highly aggressive herposi employee financial support professional advice tive form breast cancer back decade research help prepare new job opportunity roche currently lead wave innovative development combat severe tumour new breast cancer drug establish translational clinical research center perjeta approve food drug administration new york keeping presence east coast june priority review therapy combination united states center accommodate employ design overcome treatment resistance whilst target ee support clinical trial early development pro multiple pathway cancer gramme continue collaboration academic important clinical trial patient treat institution biotech company perjeta herceptin chemotherapy live significantly long receive standard therapy companion go forward convince take right diagnostic test patient likely respond measure continue benefit come target medicine quickly identify overall expect achieve sale growth constant exchange rate line roche add group medicine file regulatory group result previous year target core earning approval new drug antibodydrug conjugate know share grow ahead sale base outlook trastuzumab emtansine tdm roche forefront antici pate able raise dividend develop antibodydrug conjugate adcs currently clinical development adc combine speci ficity antibodie power chemotherapy target cancer cell directly significantly reduce effect systemic chemotherapy risk death breast cancer patient receive tdm show trial lower receive standard treatment severin schwan chief executive officer promise drug currently study global pro gramme chronic lymphocytic leukemia nonhodgkin lymphoma potential improve mabthera rituxan current standard care fighting hematological tumour addition oncology roche focus dis ease area high unmet medical need field neurosci ence alzheimer disease schizophrenia metabolic inflammatory autoimmune disease despite recent decision terminate dalcetrapib clinical pro gramme roche remain committed develop medicine patient cardiovascular disease diabete dis cover develop new drug mean take calculate risk road real innovation letter shareholder roche business report board director dr franz b humer prof bruno gehrig andr hoffmann dr andreas oeri prof pius baschera prof sir john irving bell paul bulcke william burns lodewijk j r de vink dr christoph franz dame deanne julius dr arthur levinson board director december peter r voser prof beatrice weder di mauro roche business report managementboard director year birth term end elect board director dr franz b humer e chairman prof bruno gehrig c e vicechairman andr hoffmann c e vicechairman prof pius baschera e prof sir john irving bell b e paul bulcke b e william burns e lodewijk j r de vink b e dr christoph franz c e dame deanne julius b e dr arthur levinson c e dr andreas oeri e peter r voser c e prof beatrice weder di mauro b e secretary board directors dr gottlieb keller honorary chairman board directors dr fritz gerber corporate governance sustainability committee b audit committee c remuneration committee presidiumnomination committee e nonexecutive director committee chairperson board director th annual general meeting agm roche holding ltd march shareholder reelect john bell andr hoffmann franz b humer member board director term year provide article incorporation management roche business report corporate executive committee dr severin schwan daniel oday roland diggelmann dr alan hippe silvia ayyoubi dr gottlieb keller dr richard scheller dr mike burgess dr sophie kornowskibonnet corporate executive committee december osamu nagayama dr stephan feldhaus roche business report managementcorporate executive committee year birth position corporate executive committee dr severin schwan ceo roche group dr alan hippe chief financial officer daniel oday coo division roche pharmaceutical roland diggelmann coo division roche diagnostic dr gottlieb keller general counsel silvia ayyoubi head group human resource enlarge corporate executive osamu nagayama chairman ceo chugai committee dr richard scheller head genentech research early development gre dr mike burgess head roche pharma research early development pre ad interim dr stephan feldhaus head group communications dr sophie kornowskibonnet head roche partnering secretary corporate executive committee perolof attinger statutory auditor kpmg klynveld peat marwick goerdeler sa reporting year roche holding ltd kpmg ag auditor charge john morris ian starkey chief compliance officer dr urs jaisli john c reed assume position head pharma research early development pre april member enlarge corporate executive committee corporate executive committee sophie kornowskibonnet appoint head roche partnering join enlarge corporate executive committee febru ary mike burgess assume adinterim position head pharma research early development pre july member enlarge corporate executive committee daniel oday appoint coo roche pharmaceutical division roland diggelmann coo roche diagnostic division appointment effective september management roche business report value innovation possible new medicine herpositive metastatic breast cancer new generation cancer treatment treat cancer oncologist look medicine deliver good result few effect advance area mean physician soon able prescribe treatment effective well tolerate exist therapy latestage drug candidate trastuzumab emtansine tdm able deliver potent dose chemotherapy cancer cell chemotherapy link active antibody potentially reduce effect traditional therapy devel oping drug limit impact chemotherapy provide true value pre scribers patient prof paul ellis guy hospital investigator emilia trial hope patient actually need traditional systemic cytotoxic chemotherapy expose way debilitate effect normally associate agent think apart effectiveness real legacy new type treatment tdm tdm tdm antibodydrug conjugate work potent cytotoxic agent dm drug tra tuzumab chemotherapy stable linker call dm linker linker connect trastu monoclonal zumab dm tdm antibody trastuzumab bind herpositive cancer cell think block outofcontrol signal cancer grow call tdm bind receptor bodys immune system tumour cell surface initiate antitu attack cancer cell mour activity absorb tdm absorb cell inside cell tdm break cancer cell release active form dm dm design destroy bind protein structure play release dm key role cell division prevent cell dividing ultimately result cancer cell death web httpwwwrochecomvalueofinnovation trastuzumab active ingredient herceptin roche business report value innovation tdmenindd evolution therapy herpositive metastatic breast cancer chemotherapy target therapy highly targeted chemotherapy antibodydrug conjugate tdmenindd swiss franc core earning share roche business report business review reach financial target deliver strong growth emerge market strengthen operate free cash flow lower net debt improve r efficiency roche business report business review key figure group sale millions chf cer core operating profit million chf cer net income millions chf cer millions chf change sale cer chf usd group sale pharmaceutical division diagnostic division core operate profit pharmaceutical division diagnostic division operate free cash flow core earning share chf group result outlook roche deliver strong performance reach emerge clinical product pipeline group core operate financial target year group sale increase margin improve percentage point billion swiss franc swiss franc reflect strong demand oncology product clinical group core earning share eps exclude laboratory diagnostic product emerge noncore item global restructuring charge market especially china brazil main regional amortisation impairment goodwill intangible asset growth driver western europe despite rose resilience pricing pressure sale slightly low additional pressure generic competition roche take decision restructure pharma research early development resource group core operating profit rise billion swiss available grow number product latestage franc solid sale performance combine pro development closing nutley site process ductivity improvement lower cost sale ratio underway restructuring measure take r cost stable saving closure diabetes care apply science business enable nutley site new jersey usa reinveste strong unit well adapt increasingly challenging market condition cost restructuring activity num state growth rate calculate constant exchange rate cer ber onetime item result slightly high net roche business report business reviewincome ifrs basis billion swiss franc pharmaceutical division sale region swiss francs united states pharmaceuticals western europe strong growth oncology japan sale pharmaceutical division rise billion swiss franc robust demand international selling product mabtherarituxan herceptin avastin avastin growth support launch constant exchange rate average fullyear ovarian cancer europe division additionally benefit strong demand rheumatoid arthritis medicine actemraroactemra product group strengthen show superiority monotherapy adalimumab launch perjeta filing trastuzumab emtansine adacta trial hepatitis c drug pegasy newly tdm new generation cancer treatment approval launch skin cancer medicine zelboraf perform europe perjeta tdm allow roche year build longterm success herceptin standard care woman herpositive metastatic breast cancer herceptin mabtherarituxan avastin actemraroactemra particularly aggressive form disease zelboraf pegasys represent portfolio generate billion swiss franc additional sale pipeline remain robust deliver positive result year latestage study include strong result avastin platinumresistant recurrent ovarian cancer new cancer drug launch perjeta aurelia trial breast cancer erivedge advanced basal cell carcinoma type skin cancer initial uptake product positive sale eye medication lucentis wet agerelate macular pharmaceutical division degeneration wamd fall competitive pressure sale growth e lead emerge market intensify uptake lucentis treat indication diabetic macular edema strong bonviva brazil boniva cellcept sale lower ongoing generic erosion particularly western europe china regionally sale key seven emerge india market main growth driver strong demand oncology product increase health mexico care spending number market sale western europe impact generic competition continue russia price pressure major product include herceptin mabtherarituxan avastin continue grow south korea zelboraf emerge key growth driver japan post sale growth year mircera avastin turkey mabthera perform strongly constant exchange rate average fullyear roche key seven emerge market refer e key emerge market brazil china india mexico russia south korea turkey business review roche business report pharmaceutical division core operating profit increase diagnostic division sale region billion swiss franc result strong sale efficiency gain core operating profit margin increase europe middle east africa emea north america diagnostic asiapacific strong clinical lab sale diagnostic sale increase billion swiss franc latin america continue grow fast global ivd market show slowdown market share roche japan solidly maintain market leadership divisional sale drive business clinical laboratory particularly constant exchange rate average fullyear professional diagnostic grow twice fast global market tissue diagnostic molecular diagnostic near patient testing diabetes management expand test menus division large overall product contributor growth progress personalise healthcare strategy immunoassay business help diagnose ongoing biomarker companion diagnostic project disease highly automate immunochemical blood roche pharmaceutical new agreement con testing clude external pharmaceutical company diabetes care apply science business face core operating profit diagnostic division fall challenging year reimbursement cut blood glucose moni billion swiss franc reflect increase price pressure tore product europe intensify price pre diabete care margin achieve sure impact sale diabetes care business month year percentage point decline sale apply science business low result low public research funding competition gene sequence business undertake restructuring year sustain longterm profitability refocus strong group operate free cash portfolio future growth flow improve net debt position division consolidate expand lead market posi operate free cash flow remain strong rise tion region asiapacific latin america profes billion swiss franc contribute low net sional diagnostic remain main growth driver debt position billion swiss franc end strong contribution diabetes care latin america billion franc start year result clinical laboratory business key growth driver strong cash flow bond total nominal value north america launch major product billion euro buy early start create growth momentum emea region europe middle east africa austerity mea sure pricing pressure impact sale particularly outlook diabetes care japan sale grow time rate market drive professional diagnostic roche expect group sale increase line sale growth record constant exchange rate division launch major product key market core eps target grow ahead sale roche expect year represent important advance lab automation increase dividend estimate ivd market growth source company independent report end september roche business report business reviewmarket environment group strategy healthcare market continue drive compet challenge ing pressure supply financial resource increase demand well healthcare outcome cost rise life expectancy high incidence chronic dis effective target medicine diagnostic like ease significantly increase need rapid scientific produce roche key role play tackle technological advance well health outcome challenge market trend affluent west constitute fast grow public health problem develop country despite advance modern medicine need improve healthcare treatment remain enormous pharmaceutical market know disease twothird remain untreatable pharmaceutical market continue expand world lack satisfactory treatment grow age world wide pace growth slow population accelerate demand medicine go patent global sale forecast andolder population forecast triple billion reach trillion swiss franc give rise agerelate chronic disease cancer diabetes alzheimer disease age emerge market show robust growth cre lifestylerelated disease long problem ate new opportunity pharmaceutical industry government invest public healthcare system china expect main contributor global growth regional market share global pharma sale growth develop market expect stay modest good large healthcare market usa growth rate forecast slow low gdp growth increase generic competition europe speciality pharmaceutical market large china fast grow healthcare segment total market share datum source im large share japan growth key growth area oncology brazil russia autoimmune disease general hospital biolog india ics segment roche global leader canada diagnostic market global vitro diagnostic market estimate approxi rest world mately billion swiss franc grow slow pace expect grow average rest emerge market annually long term source independent ivd consultancy high growth rate forecast im health market prognosis april emerge market molecular tissue diagnostic business review roche business report global need new well treatment option diagnostic division work support develop increase pressure control healthcare ment reimbursement programme accurately assess cost europe particular economic condition validity advance diagnostic testing drive cost efficiency measure put pressure healthcare industry deliver innovative solution low cost business model change practice medicine additional condition introduce regula tory process approval new medicine new legislation decade roche maintain strategic focus encourage comparison medical treatment innovative diagnostic therapeutic today basis safety efficacy additionally intensify commitment develop personalise health cost increase influence nonprescribe decision care medically differentiate product medicine maker evident market uk ger diagnostic create superior value patient staterun organisation review clinical customer society advance goal focus exclu wide economic benefit new medicine comparison sively prescription pharmaceutical vitro diagnostic establish product market health technology follow business model drive medical innovation assessment common europe dimension evaluate reimbursement decision medical evidence fitting treatment patient comes frequently valuebase pricing system pursue excellence science payment structure treatment outcome deliver value stakeholder health system globe generally increase focus clinical outcome real world evidence datum fitting treatment patient enable real value new medicine assess eighteen million patient treat roche medicine product launch pharmaceutical industry active year patient participate clinical working health authority structure clinical trial trial new drug develop patient frame provide evidence medical value quickly inno strategy discover develop new medicine vative medicine reach patient quickly diagnostic decide molecule research design clinical trial focus innovation new diagnostic technique enable develop thera pie increasingly target particular patient researchbase healthcare company roche focus population patient diagnosis innovation invest significantly r develop highly dif respond different way medicine patient ferentiate effective treatment help people live long help treatment experience healthy life personalise healthcare roche unwanted effect desire clinical benefit example strategy pinpoint exactly patient variability genetic biological respond particular therapy ensure patient difference patient receive right treatment right time wast age healthcare budget target approach deliver draw insight difference molecular value healthcare stakeholder patient providers reg level develop treatment test tailor ulator payer effective diagnostic testing play need specific patient population personalise important role increase overall efficiency healthcare approach enormous potential healthcare well delivery spending vitro diagnostic repre safe costeffective additionally medically sent healthcare expenditure medical differentiate product likely obtain regulatory decision depend accurate fast diagnosis approval accept patient physician payer turn reduce healthcare cost considerably owe significant clinical benefit roche new cancer demonstrating value strategic priority roche medicine erivedge zelboraf perjeta received accelerate collaborate extensively healthcare provider insurer approval market approve payer particular value timely accurate companion diagnostic today roughly half new molecular diagnosis fully recognise entity latestage portfolio tailor subset roche business report business reviewpatient identify diagnostic test productivity research development central personalise healthcare year roche achieve positive latestage trial success rate clearly industryaverage pursue excellence science excellence science discovery innovation combine strong inhouse research capability answer medical challenge world face continu late advance science biotech company ously invest research development seek gain partnership today onethird pipeline well understand disease harness potential market product originate external net modern biological science treat disease work foster innovation interact academic roche invest billion swiss franc institution university worldwide r past year com panie world deliver value stakeholder formation roche valuable contribution science rapidly expand knowledge disease biology society discovery development novel cause disease hold particular promise transform therapy improve health help patient live long practice medicine knowledge lead well live dramatic improvement identify biological target fight disease complexity research rise signifi continue success hinge largely ability combine cantly result lengthy costly r cycle social environmental responsibility focus sus new product year approximately billion tainable economic growth roche convince sustain swiss franc average obtain approval new drug able corporate policy practice promote innovation time increasingly stringent regulation slow create longterm value stakeholder approval new molecular entity industry patient doctor ensure product quality safety improve access medication enable medical excelling science achieve breakthroughs laboratory work efficiently help contain science technology need speed discovery healthcare cost development approval new medicine interweave employee give people opportunity knowledge pharmaceutical diagnostic divi mark improve life create great place work sion value chain increase efficiency embrace diversity organisation roche strategy leverage pharmaceutical diagnostic discovery market pharmaceutical research development commercialisation unrestricted knowhow efficient fast adoption phc solution ip exchange development medicine test technically validate clinically validate research assay ivd assay ivd assay diagnostic business review roche business report investor ensure transparency achieve superior structure build innovation valuation industry peer aim provide master complex biology disease total shareholder return quartile industry pathway big challenge develop new diagnostic peer set test medicine overcome challenge community stimulate engagement science pro encourage people consider different perspective mote cultural activity tackle social cause approach drug research early development lasting impact structure business foster creativity excellence society large conduct business responsibly science view positive influence society minimis ing impact environment roche recognise complementary inhouse research early develop supersector leader healthcare fourth time ment arm pre gre roche diagnostic row dow jones sustainability index chugai operate independently group believe decentralised approach combine critical mass roche group flexibility creativity management model enable entrepreneurial spirit common small busi innovationdriven culture ness time consolidate coordinate groupwide activity clinical development manufacture management model aim enable culture inno marketing commercial operation good use vation embrace diversity approach like busi global scale reach ness model dimension inspire integrity courage passion people encourage accountable transparent decision make structure business capitalise innovation people integrity courage passion ability leverage combine expertise pharmaceu tical diagnostic ultimately depend people rep resent virtually country globe employee bring work diversity perspec tive experience stimulate creativity innovation respect embrace value diversity actively fos ter high standard integrity courage reach boundary passion improve patient live integrity passion courage value seek company bind team constantly grow decision make accountable transparent believe good leadership question hierarchy function effective decision making give highly network organisation complex nature busi ness decision inform dialogue system atic factbase open transparent decision require single accountable decision maker collect criti cally review information compete view empowerment essential delegate decision make possible low qualified level organi sation roche business report business reviewspecial feature fight cancer go year cancer research roche people develop cancer lifetime start aim advance treatment cancer challenge find cure remain elusive result roche later develop successor drug reason difficult treat cancer strictly speak aim preferentially generate cytotoxin fu e disease group different disease tumour consequently achieve great effi far different type identify cacy few effect cer common cause uncontrolled proliferation human cell early beginning cancer research conduct roche provide doctor patient bet roche forefront cancer research dec ter well medicine diagnostic agent ade today lead pharmaceutical diagnostic company field year ago robert duschin cancer cell unfortunately inventive discover way sky picture nutley collaboration charle escape treatment reproliferate later stage heidelberger university wisconsin synthesize despite tremendous progress treatment cancer fluorouracil fu roche anticancer drug remain combat insidious disease consider breakthrough time cause severe effect attack healthy cell cancer cell special feature roche business report longrunne battle cancer contribution diagnostic tumour marker global guideline pain cancer mortality start decline blood management intensive exposure sunlight radiotherapy chemotherapy treatment earlystage colon recognise cause skin cat scan cancer cancer virus cause cancer hpv medicine increase red natural cytostatic breastconserve surgery blood cell production patient cancer treatment anemia target biopharmaceutical cancer medicine produce relationship demonstrate biotechnology obesity cancer foundation molecular molecular diagnostic test advance diagnostic cancer detection fluorouracil enzyme immunoassay epoetin beta fu synthetic substance roche detection tumour antigen neorecormon inhibits cell growth treatment chemotherapy administer intravenously induce anemia cause tumour shrink alphainterferon roferona attack divide cell roche biotechnological include healthy one product approve treatment filgrastrim neupogen previously fatal form blood cancer prevent white blood cell depletion positive response rate risk infection chemotherapy procarbazine natulan case treatment lymph tissue tumour retinoic acid vesanoid active substance interfere genetic treatment acute promyelocytic material dna disrupt doxifluridine leukemia cell division furtulon devel opment fu design rituximab generate active fu prefer mabthera tar entially tumour result get biotechnologically few effect produce drug treatment nonhodgkin fluorodeoxyuridine lymphoma blood cancer floxuridine fu derivative indication capecitabine xeloda orally adminis tere inactive precursor fu design generate efudix cream contain fu doxifluridine absorb local treatment skin tumour gut reduce risk intestinal damage world immuno trastuzumab diagnostic test tumour marker herceptin biotechnologi cea carcinoembryonic antigen cal drug treatment particularly aggressive positive form breast cancer accounting breast cancer high protein level detect companion diag nostic test treatment example medicine gear need specific patient group personalise healthcare roche business report special feature decode human genome record number cancer survivor cancer cell resistant firstline drug breakthrough medicine skin cancer combination treatment target drug new drug class antibodydrug conjugate medicine inhibit tumour blood supply personalise cancer therapy cervical cancer vaccine companion diagnostic test genetic tissue cancer test combination treatment resistance bevacizumab avastin biotech vemurafenib zelboraf compan nological cancer drug block angiogenesis ion brafve mutation detection test word formation blood vessel mutate form braf protein occur supply cancer tissue nutrient oxygen half melanoma patient companion specifically block naturally occur protein test identifie patient specific mutation vegf vascular endothelial growth factor zelboraf launch targeted attack important mediator angiogenesis avastin pos tumour make treatment aggre sesse novel mechanism action sive skin cancer considerably improve quality type tumour life prolong survival erlotinib tarceva oral lung cancer important new oncology test drug inhibits tumour development attack include cobas hpvin detect woman heregfr protein important cell increase risk cervical cancer growth vismodegib erivedge oral target drug treatment advance inoperable metastatic basal cell carcinoma erivedge specifi cally block mediator hyperactive signal path way cancer cell pertuzumab perjeta biotechnological drug treatment particularly aggressive form breast cancer positive combination chemotherapy herceptin dimerisation inhibitor design specifically prevent receptor pair receptor special feature roche business report cancer grow global challenge cancer remain unconquered cardiovascular disease cancerrelate death claim victim year million people world worldwide wide diagnose cancer million people die annually form cancer develop coun try account half case cancer kill lung people year aid malaria tuberculosis combine stomach cancer increase chiefly grow liver age world population breast lung prostate cancer frequently diagnose industrialise country colorectal unhealthy lifestyle choice contribute increase breast cancer estimate cancer prevent avoid behaviour smoke alcohol abuse condition like overweight recent progress diagnosis treatment cancer contribute encourage overall improvement survival medically promise approach include well early detection rate advanced case survival breast cancer combination treatment regimen different patient example triple effect attack tumour new angle today target medicine effect adapt genetic change tumours usher new era cancer therapy currently year million people diagnose cancer estimate age standardise incidence rate cancer exclude nonmelanoma skin cancer sex age reference international agency research cancer globocan cancer fact sheet access online httpglobocaniarcfr roche business report special featuregaine well understand insidious disease cancer difficult control important finding signal chain function disrupt mutation research molecular level cancer collective corresponding gene involve antenna term tumour affect cell membrane cell surface receptor bodys tissue occasion multitude sign symp partly responsible controlling signal pathway trigger tom late effect ing cell division multiplication hyperactive lead ing uncontrolle cell division proliferate cell ultimately type cancer damage dna displace damage healthy tissue change gene genetic defect cause tumour extent inherit researcher roche work identify characteris acquire course life cancerengendere tic change genome signal pathway substance tobacco virus radioactive ray particular tumour aim combat cancer damage gene cell blueprint effectively block overactive mechanism tumour develop mainly cell display gene change mutation change affect important cellular mechanism normally control cell proliferation signal pathway trigger cell division proliferation cancer pathway disrupt rtk pip pip pten ras pa p pik tsc raf akt tsc mek erk cyclin forkhead bad mtor cell cycle proteinsynthesis p fasl bcl progression growth proliferation survival special feature roche business report improve survival benefit cancer patient advance cancer medicine year pro survival benefit new cancer medicine well long life improve quality life considerably cancer indicate new treatment initially patient year ago patient advanced breast cancer advanced stage disease unfortunately patient live month diagnosis average today live situation experience series treat time long ment failure lead understatement sur vival benefit new medicine progression overall survival average month advanced cancer decade lung cancer glioblastoma colon cancer kidney cancer gastrointestinal stromal tumour breast cancer ear nose throat cancer multiple myeloma malignant bcell lymphomas month year old treatment new treatment average value variety treatment source prof christoph zielinski university vienna march optimise outcome treatment malignant disease modern treatment strategy impact cancer patient survival httpwwwonkologiewienatforschungundlehrepositionspapier roche business report special featurepromise research cancer treatment future roche direct billion swiss franc annually gear human immune system attack tumour cell oncology research entire expenditure r effectively pdl antibody block pdl protein find tumour prevent immune pursue variety strategy gain increas system cell destroy malignant cell ingly well molecular understanding cancer lead glycoengineere antibody ga bind improve detection new broad treatment tumour cell attract immune system cell recent advance include tlymphocyte natural killer cell destroy drug combination block array signal pathway flag tumour cell spiral control cancer prevent development resistance tumour cell target therapeutic agent combine new type target selective cancer therapy anti companion diagnostic test predict probability bodydrug conjugate kill cancer cell exert patient respond treatment personalise approach minor negative effect normal tissue cancer treatment well patient enable efficient use financial human resource national health system roche oncology portfolio broad set technology target therapy tumour type gastric colorectal lung skin gliobla hema positive negative stoma tological breast breast antibodydrug tdm tdm anticd conjugate anticd b antibody perjeta perjeta metmab metmab metmab metmab combination herceptin herceptin avastin avastin avastin avastin egfl egfl avastin avastin glycoengineere ga ga ga antibodie obinutuzumab immuno eg zelboraf therapie pdl small pik pik zelboraf bcl molecules meki pik special feature roche business report expert view susanne arbogast pathologist oncology franchise roche project design produce new cancer drug combine biomarker programme probe analysis begin preclinical stage lead license diagnostic test pioneer use primarily phase iii project fact number biomarker study conduct collaboration external ner inhouse considerably exceed number pharma project explore avenue simultaneously classify marker insight response particular therapy screen patient tumour sample differ ence level gene dna molecule transfer genetic information rna gene product protein cancer diagnostic appear set evolve single test approach simultaneous testing parameter order identify good possible treatment particular patient roche business report special featurehal barron chief medical officer progress oncology therapeutic area year incredibly robust addition receive regulatory approval new molecular entity cancer month result key clinical trial oncology nononcology medicine positive result success rate mean basically week news result meaningful impact patient likely factor contribute successful study include rigourous early research efficient study execution smart risk focus personalise healthcare identify patient likely benefit certain medicine combine measure talented people increase probability technical success allow deliver transform medicine patient special feature roche business report collaboration pharmaceutical diagnostic roche business report research development receive approval new cancer medicine deliver positive result latestage clinical trial continue clinical development promise new molecular entity launch diagnostic product key market roche business report research development key figure core research development r expenditure roche group millions chf cer sales pharmaceuticals millions chf cer sale diagnostic millions chf cer sale employee r roche group pharmaceutical diagnostic constant exchange rate average fullyear highlight pharmaceutical milestone compound indication approval erivedge advanced basal cell carcinoma perjeta metastatic breast cancer approval eu zelboraf braf v mutationpositive metastatic melanoma avastin recurrent platinumsensitive ovarian cancer filing tdm metastatic breast cancer filing eu perjeta metastatic breast cancer tdm metastatic breast cancer key phase iii trial result emilia tdm add nearly month average live woman herpositive metastatic breast cancer second line cleopatra perjeta significantly extend live herpositive metastatic breast cancer patient give new drug alongside herceptin chemotherapy line adacta actemraroactemra show effective adalimumab monotherapy rheumatoid arthritis diagnostic major product launch major launch include device people diabete instrument pointofcare test system drive efficiency clinical research lab assays diagnosis cancer infection metabolic disease key clinical study result vision troponin cardiac test helps identify patient risk major noncardiac surgery abacus accuchek aviva expert bolus advisor help people diabete improve ability reach glycemic target roche business report research developmentour pipeline remain solid deliver positive result long give herceptin chemother latestage study total apy study show risk death cut new molecular entity clinical development con fident compound important therapy come year latestage emilia trial show patient positive metastatic breast cancer receive diagnostic division launch major product key treatment illness survive median month market include diabete care device vitamin long treat tdm receive test united states lapatinib xeloda risk death reduce highlight ability improve treat trial ongoing examine use perjeta ment option available woman suffer herpositive tdm woman early stage herpositive breast breast cancer particularly aggressive form disease cancer examine combination perjeta year million woman diagnose breast tdm cancer world die disease herpositive breast cancer affect approximately herceptin perjeta tdm work target woman breast cancer woman test receptor protein find abnormally high quantity type breast cancer outside cancer cell herpositive cancer perjeta herceptin complementary building success herceptin past year target receptor different place tdm par launch new medicine perjeta united states ticularly interesting compound secure positive recommendation european union example antibodydrug conjugate adc new tech committee medicinal product human use nology significant difference cancer treat file approval novel therapy trastuzumab emtansine ment tdm europe united states data late stage trial show drug disappointment second interim analysis real difference woman diagnose daloutcome phase iii trial show lack positive breast cancer year clinically meaningful efficacy dalcetrapib drug aim reduce risk cardiac event heart attack cleopatra phase iii study show woman raise highdensity cholesterol decide stop devel herpositive metastatic breast cancer treat opment dalcetrapib basis datum perjeta herceptin chemotherapy live significantly fight herpositive herceptin treat woman breast cancer early stage herpositive breast cancer give woman type breast cancer great deal hope decade ago woman diagnose survival rate significantly improve woman positive breast cancer face bleak future survival rate treat herceptin early stage patient type cancer bad illness live disease free year treatment death likely follow year diagnosis million people treat herceptin scientist discover overexpression gene know human epidermal growth factor receptor story approval perjeta blame deadly form breast cancer strong datum tdm chapter begin begin develop targeted therapeutic antibody block hergrowth factor receptor eventu ally herceptin approve woman latestage include patient treat herceptin breast cancer herpositive breast cancer stomach cancer research development roche business report antibodydrug conjugate adcs extensive pipeline adc oncology indication adcs allow patient benefit chemotherapy indication phase iii registration suffer toxic effect chemo therapy work attack healthy cancer breast tdm ous cell know securely attach chemo therapy antibody allow target delivery nhl anticdrg chemotherapy cancer cell increase efficacy decrease effect chemotherapy nhl anticdbrg hair loss nausea infection prostate antisteaprg tdm trastuzumab active ingre dient herceptin potent chemotherapy agent dm ovarian rg linker connect dm trastuzumab multiple myeloma rg roche currently adcs clinical development oncology indication optimistic soon lung ovarian rg able replicate success tdm type cancer blood cancer pancreatic ovarian rg melanoma rg diagnostic ahdowc sa dhcow w thoeryk work cceerrttaaiinn pprrootteeiinnss tthhaatt aarree nnoott ffoouunndd eellsseewwhheerree iinn tthhee bbooddyy tmhaei nm cahina lclehnagllee nisg ee niss uerninsgur tinhgat tthhaet cthhee mchoethmeortahpeyr aisp py rios p ccaann ssoommeettiimmeess bbee ffoouunndd oonn tthhee ssuurrffaaccee ooff ttuummoouurr cceellllss bbyy erly partotapcehrelyd ttota tchhee adn ttoib tohdey anntdib tohdayt aitn wdi ltlh naot ti tf awlli lol fnf oint ftahlel ff ddeevveellooppiinngg aann aannttiibbooddyy tthhaatt rreeccooggnniisseess tthheessee pprrootteeininss anndd blooidn tsht ec belrotaoidn sptrroetaemin nthda atc atr jeu snto lti kfeo ucnhde melosethwehraeprey nif tthheis aattttaacchhiinngg tthhee cchheemmootthheerraappyy ttoo tthhee aannttiibbooddyy iitt iiss ppoossssiibbllee bodhy acpapne snosm theeti mpaetsi ebnet fdoouensd noont tgheet saunryf abceen oeff itt ufmroomu rt hcee ltles ch dtoe ldiveelirv ae rt oax tionx dinir edcirtelyc ttoly tthoe hcaen ccaenrc ceerl lc aenlld pnodt penottieanlltyi aslplya reamn oalnodg yac rt ijcuhsta rlidk es cchheelmleort hheeraadp yof igf rtheisd h saapidpe ntsh itsh apsa tkieeny tshpea rree stht eo fr ethset obfo tdhye fbroomdy hfreo mim tphaec itm opf athcet ocfy tthoeto cxyicto dtoruxgic doesto n soet cguerti nagn yt bdenmefist fsruocmc ethse technology richard scheller cdhruegm ootrh cehraepmyotherapy head gred say key securing tdm success stable linker receptor chemotherapy agent dm monoclonal antibody trastuzumab cancer cell step step step trastuzumab component tdm detect trastuzumab component block cell tdm degraded releasing bind herpositive cancer cell ofcontrol signal cancer grow active dm form bind call bodys immune protein structure play key role cell divi system attack cancer cell tdm sion dm prevent cell dividing take herpositive cancer cell cell die roche business report research development tdmenindd blood cancer introduction hematology work generation target therapy common blood cancer lymphoma occur treat certain blood cancer like nonhodgkin lymphoma lymphocyte type white blood cell grow abnor nhl chronic lymphocytic leukemia cll mabthera mally main type lymphocyte develop lym know rituxan united states prove phomas blymphocyte bcell tlymphocyte extremely effective medicine hematological cancer tcell cancerous lymphocyte travel part launch treat body include lymph node spleen bone mar million patient oncology row blood organ unmet medical need area patient test cd protein surface draw understand biology bcell bcell find bcell tcell role blood cancer develop number derive cancer mabtherarituxan work target compound improve treatment hema bcells high level cd grow tological cancer abnormally obinutuzumab ga design ef main type lymphoma nonhodgkin lym fective drug mabtherarituxan obinutuzumab work phoma hodgkin lymphoma nhl common target cd protein malignant bcell bind cancer lymphatic system immune cell surface way restore natural process system expect nearly cell death apoptosis time activate bodys annual death worldwide nonhodgkin lym immune system aid cell death process know phoma antibodydependent cellmediate cytotoxicity adcc obinutuzumab clinical development programme design demonstrate superiority mabtherarituxan multiple frontline headtohead trial nhl cll phase rg selective inhibitor pmdm bind iii trial report cll stage result look gene p play central role control cell growth use firstline cll recruitment obinutu division help suppress tumour scientist try zumabs phase iii trial go find way restore function ps gene product know p damage way rg inhibit bcl protein highly express mdm gene gene work p cll indolent nonhodgkin lymphoma aggressive division cell control prevent exce lymphoma bcell neoplasm datum sive production p drug target mdm phase trial present american society hema fore allow body produce p restore normal tology ash annual meeting show antitumour activ cell growth phase result present ash provide proof ity patient mantle cell lymphoma mcl diffuse large mechanism evidence singleagent clinical activity bcell lymphoma dlbcl follicular lymphoma walden mdm antagonism leukemia demonstrate complete stroem macroglobulinemia wm remission maximum tolerate dose lysis leukemic blast activation p pathway target develop adcs target cdb cd leukemic cell additional antigen express nearly bcell lymphomas phase datum present anticdb adc rg anticd adc rg ash show targeted therapy compound promise antitumour activity acceptable tolerability profile heavily pretreate roche forge ahead development therapy patient relapse refractory bcell nhl include target abnormal gene expression disease like cancer follicular lymphoma dlbcl mcl headtohead phase onartuzumab metmab promising compound ii trial look agent combine rituximab pipeline ongoe adcs develop seattle genetic technology research development roche business report onartuzumab target therapy combination therapy number different cancer include lung cancer breast cancer colorectal cancer glioblastoma type brain tumour combination cancer medicine emerge gastric cancer result far strongly suggest onar important effective way help people cancer tuzumab work good patient express meet protein live long combine treatment possible hit investigate latestage trial use metposi pathway responsible tumour growth mean tive advanced nonsmall cell lung cancer combination medicine able overcome resistance cancer tarceva exist lung cancer therapy mid build certain treatment stage result present show combination onartuzumab tarceva triple time braf meki build extensive clinical experi metpositive patient live compare tarceva ence firstinclass braf inhibitor zelboraf investi gate number combination approach include zelboraf onartuzumab work stop protein call hepato investigational mek inhibitor gdc scien cyte growth factor hgf bind meet stop tist believe reason patient treat meet hgf come cancerous cell find braf inhibitor stop respond therapy difficult grow replicate survive spread acquire resistance drug inhibit rasraf develop tissuebase companion diagnostic test pathway initiate phase iii study explore cmet allow doctor identify likely potential investigational mek inhibitor gdc benefit onartuzumab zelboraf avastin onartuzumab preclinical study show combination avastin onartuzumab syn ergistic effect attack cancer cell growth avastin work target inhibit vascular endothelial growth companion diagnostic test factor vegf require growth new blood vessel block vegf avastin starve tumour diagnostic play key role research develop blood supply onartuzumab target meet receptor ment target medicine drive vegf expression phase ib study combina sonalise healthcare collaboration group tion avastin onartuzumab generally tolerate pharmaceutical pipeline project roche look simultaneous target vegf develop companion diagnostic meet pathway tumour type include tri ple negative breast cancer metastatic colorectal cancer glio diagnostic division test allow researcher blastoma nonsmall cell lung cancer accurately identify molecular abnormality cause dis ease allow researcher drug tailor specific patient result drug effective look future oncology therapy dose optimal reduce unnecessary effect roche work new type cancer treatment combination specific diagnostic test target restore patient immune system attack therapy improve prognosis cancer tumour antipdl roche cancer immunotherapy patient companion diagnostic test help programme clinical development goal significantly treatment infectious disease like hepatitis c improve durable survival number human cancer anti pdl human monoclonal antibody engineer restore work diagnostic testing shed patient exist immunity generate new immunity light certain tumour resistant target drug therapy roche uniquely position leader cancer immuno therapy base wealth experience knowledge roche confident able use com immunology oncology continue research panion diagnostic number disease area apart develop antipdl molecule monotherapy cancer immunology neuroscience combination treatment incorporate bio roche business report research developmentongoe combination therapy trial phase phase ii phase iii launch antipdl avastin onartuzumab avastin perjeta herceptin perjeta herceptin solid tumour triple neg mbc adjuvant herpositive herpositive bc mcrc bc aphinity nsclc nonsquamous l recurrent glioblastoma antipdl antiegfl avastin tdm perjeta zelboraf braf nsclc l herpositive bc l metastatic melanoma mcrc l marianne braf mut herpositive bc ebc anticd adc anticdb adc mabthera hematologic malignancy zelboraf braf meki rg marker research enhance understand science cancer immunotherapy treat untreatable new way treat cancer future come roche develop therapy number central unexpected source toxin bacterial nervous system cns disorder recently infection exotoxin exotoxin kill cell believe untreatable particular pseudomona exotoxin pe prove important agent treatment cancer extremely people autism example traditional potent cell killer far toxin prove impossible thinking luca santarelli harness therapeutic usage bodys immune head neuroscience say system reject new datum show medicine develop collaboration national cancer insitute nci illnesse autism fragile x syndrome down explore use deimmunise version pe war syndrome refractory depression early stage head attach antibody fragment peptidergic binder alzheimer disease molecule call cytolytic fusion protein cfp agent development strong neuroscience pipeline advance target pleural mesothelioma cancer industry roche considerable progress area treatment option aim cfps decade group nearly dozen human result clinical proof con compounds development cns cept able quickly develop number followon molecule target different cancer allow shortcuts cns development santarelli advantage flexibility platform say gantenerumab alzheimer year make neuroscience work closely academic institute external bio tech company form publicprivate partner past year scientist gain well ship help roche develop presence field stand brain today roche work new mole development companion diagnostic cular entity generation medi critical particularly alzheimer cine range disease include schizophrenia multiple difficult disease diagnose properly research development roche business report sclerosis depression neurodevelopmental disorder parkin gantenerumab significantly decrease level amyloid son disease alzheimer disease brain currently conduct phase iiiii trial gantenerumab call scarlet road c ompanion tackling disease central nervous system cns diagnostic identify patient early ensure focus biology illness take similar patient enrol display alzheimer disease pathology approach development cancer therapy biomarker result scarlet road expect help develop target treatment cns disorder alzheimers gantenerumab compound select worldwide trial investigate antiamyloid agent prevent alzheimer dominantly inherit alzheimer alzheimer disease network trial conduct washington university school medicine st louis usa advanced compound treatment alzheimer gantenerumab crenezumab crenezumab phase ii trial abby blaze mild moderate alzheimer result trial gantenerumab aim treat patient alz crenezumab government heimer year early currently back trial preclinical alzheimer determine treat slow prevent help prevent slow disease study investi damage brain gantenerumab initially devel gating use crenezumab group colom oped partnership morphosys investigate bians genetic mutation result develop patient prodromal alzheimer show sign alzheimer forty far drug show mild cognitive impairment evidence amyloid effect mean high dose potentially plaque brain early clinical study show increase get brain crenezumab antibody target solid bit beta amyloid plaque brain freefloate soluble form abeta protein alzheimer disease alzheimer devastating impact live patient schizophrenia family common form dementia approximately million people suffer alzheimer roche working improve live people schizo worldwide estimate million people phrenia chronic brain disease affect approximately affect million people million people common disable disease population age condition worldwide symptom schizophrenia fall main category positive symptom hallu alzheimer notable clinical symptom common cination delusion negative symptom lack people age people certain rare speech lack emotional expression inability begin genetic mutation develop disease early sustain activity social withdrawal cognitive deficit include difficulty memory attention decision people alzheimer abnormal amount amyloid make reduce signal nmda nmethyld protein amyloid plaque brain buildup protein aspartate receptor think possible explanation reduce effectiveness healthy neuron gradually symptom destroy detect level protein spinal fluid identify patient alzheimer bitopertin new firstinclass oral glycine reuptake inhib high risk converting dementia itor design improve nmda receptor function year time phase iii trial searchlyte trial programme investi gate bitopertin combination standard care anti believe approach treat alzheimer early psychotic patient predominant negative symptom stage prodromal pioneer roche currently daylyte flashlyte sunlyte suboptimally compound clinical development alzheimer control symptom schizophrenia moonlyte twilyte nightlyte roche business report research developmentidentifye risk multiple sclerosis develop ocrelizumab new therapy multiple develop immunoassay identify sclerosis ms debilitate neurological illness ocrelizumab patient high risk develop alzheimer humanise monoclonal antibody design selectively disease develop genetic test apoliprotein target cdpositive bcell think play e identify carrier apoe genotype important role ms work bodys immune system benefit dose adjustment gantenerumab eliminate cdpositive bcell ocrelizumab phase immunoassay tau iii clinical trial patient relapse form dis exploratory surrogate marker efficacy ease opera ii patient primary progre sive form ms oratorio approve immunoassay technique determine treatment level antigen antibody oxford medical dictionary diagnostic diagnostic division advance lab automa develop new technology tion near patient testing diabete management newly launch test aid diagnosis cancer invest new technology infectious disease metabolic disorder important difference way certain disease cancer diagnose example microrna united states large market launch vitamin multiplexing tissue diagnostic business test diabete care devices accuchek nano smartview discreet blood glucose selfteste accuchek microrna play important role tumour combo pumpmetre combination accuchek inform ii control expression oncogenic protein influ professional glucose testing hospital rest ence treatment resistance cancer spread world key launch cobas b system roche tissue diagnostic develop fully auto doctor office outpatient clinic help identify mate stain technique allow researcher detect manage patient metabolic disorder microrna protein tumour microenvironment help researcher well understand cancer develop new target therapy drive testing efficiency multiplexing technology allow simultaneous iden develop diagnostic platform test tification different target mutate gene enhance testing efficiency clinical laboratory protein single piece tissue mean phy research centre number system early sician able answer time initial latestage development include nextgeneration platform diagnosis tumour tissue available immunodiagnostic clinical chemistry coagulation test comparison case cancer return ing lead cobas series fully automate analyser design help large lab consolidate remain focused develop fast efficient work area handle expand testing volume sequence system nextgeneration sequence allow develop cobas novel molecular scientist examine part person genome fast testing platform expect offer new level efficiently continue collabora automation throughput costefficiency molecular tion external partner nextgeneration platform blood screen laboratory invest sequence workflow enhancement initiate collaboration precision system science genome total genetic material organism comprise gene contain chromosome oxford medical dictionary research development roche business report diabete care pump cgm late start guideit clinical trial investi gate benefit heart failure test ntprobnp ther roche continue develop innovative integrate diabe apy monitor heart failure patient pivotal trial co te management system help patient caregiver ordinate duke clinical research institute main study optimise therapy focus investment insulin fund national institutes health pump continuous glucose monitor cgm roche ntprobnpguide heart failure care expect great market potential innovative differenti substantially reduce occurrence cardiovascular event ate product pipeline include nextgeneration insu worsen heart failure hospitalisation death lin pumpblood glucose metre accuchek insight compare current standard care novel micropump follow decision cancel micropumps pilot launch late devel oping product combine metre pump continue study new diabetes management approach prove accuchek feature develop cgm base innovative device abacus study investigate system provide real time continuous glucose monitor use accuchek aviva expert automatic bolus advi e small sensor patient skin cgm sys sor functionality calculate appropriate insulin dose tem early development deliver promising result base regular blood glucose monitor insulin depen clinical study dent patient study result present october reveal use bolus adviser improve ability reach glycemic target support therapy adherence patient wellbee increase number hypo automate emulsion pcr instrument preparation glycemic event genomic sample improve r productivity provide medical value improve productivity r priority roche develop test provide new answer area work r practice efficient order oncology virology metabolism example develop medicine sustainable way reduce time cobas pikca mutation assay design takes bring product market detect mutation pik phosphoinositide kinase pathway pathway mutate cancer patient approach design trial ensure shorter develop play significant role colorectal gastric ment time biomarker example able breast endometrial tumour select patient likely respond treat ment mean run smart trial test research use launch early likely successful allow reduce cost ivd test predict response specific cancer therapy trial patient develop launch come year early development test identify variation gene expression initiative trial patient tp aim well inform pik pathway tumour tissue companion patient doctor benefit participate diagnostic page cmet apoe tau clinical trial develop online recruiting tool easy patient enrol deliver clinical evidence enrolment clinical trial increase programme like tp able accelerate drug development invest collaborate clinical trial instance cancer patient participate trial patient demonstrate medical value diagnostic product enrolment time cut year help physician well monitor treat patient suffer ing illness heart disease diabetes guide evidencebase therapy biomarker intensify treatment polymerase chain reaction automate bolus advisor control usability study roche business report research developmentyear currently require accord national cancer stembancc partnership institute roche play lead role stembancc exciting effort streamline r activity new academicindustry partnership help deepen take difficult decision close site nutley new understanding number complex disease initiative jersey united states closure allow allocate improve drug development process resource expand latestage pipeline focus promise agent stembancc project involve pharmaceutical company academic institution base nobel prize win technology revolutionise way stem access external innovation cell research approximately active partnership molecule long time believe adult cell divide party account onethird roche cell type example skin cell sale external innovation continue valuable con skin cell liver cell tribution pipeline allow broaden global liver cell innovation network recent year researcher develop way roche partnering sign new agreement includ reprogramme ordinary adult cell create stem cell e product transaction research tech generate kind cell stem cell nology collaboration addition product outlicence know induce pluripotent stem cell scientist agreement sign team main transaction john gurdon cambridge university shinya yamanaka exclusive partnership versant venture kyoto university award nobel prize physiology inception sciences create drug discovery incubator medicine finding inception treatment sensorineural hearing loss deal structure particularly innovative involve advance mean blood skin cell venture firm versant provide equity financing phar sample patient examine disease petri maceutical company roche contribute funding dish technology allow test potential small resource research biotech firm inception molecule biologic treatment early stage provide innovative technology platform drug discovery process drug hunting expertise inception science team project launch roche innovative genentech partnering sign new agreement medicine initiative end focus diabete include product transaction research tech central nervous disorder include dementia autism nology collaboration academic collaboration schizophrenia peripheral nervous system dis outlicence agreement enter unique deal order especially pain partnership run year structure usbased constellation pharmaceutical include future option acquire constellation base pre roche scientist work induce pluripotent stem negotiate term major strategic agreement base cell partner harvard university massachusetts science epigenetic chromatin biology discover general hospital year create develop treatment cancer disease human induce pluripotent stem cell line model cardiovascular disease recently diagnostic division sign licensing agree join force boston childrens hospital harvard ment tender offer group illu use stem cell model neurological disease mina reject research development roche business report conduct responsible r animal research roche contract research organisation clinical trial mice rat clinical trial critical determine safety efficacy rodent rabbit new medicine clinical trial compliant good clinical practice guideline international quality dog standard information trial share regu latory authority payer regardless outcome primate trial roche dedicate provide balanced information trial healthcare professional public perform trial country intend market med icine test patient involve clinical trial bioethic roche publish position paper r activ clinical trial itie area genetics stem cell animal research routinely review update position pol icie research involve human animal take number clinical trial account scientific development public concern number healthcare centre involve roche charter genetic ensure genetic number patient research meet high standard socially responsi phase iiv clinical trial ble believe right individual selfdetermi nation privacy confidentiality collection exclude noninterventionist screen programme use genetic information detail clinical trial available wwwrochetrial animal welfare com wwwclinicaltrialsgov international fed public concern animal research seriously eration pharmaceutical manufacturer association work maintain high clinical trial portal national institutes health standard animal welfare possible seek alter global registry native use animal computer simulation vitro testing differentiated cell stem cell roche encourage scientist publish result work put risk reliability validity research test medical journal present scientific medi result follow rs approach cal congresse scientific article reduce number animal need roche scientist publish lead journal refine tailor procedure minimise pain dis nature cell science new england journal medicine comfort replace method involve animal use cell tissue animal ethical practice animal research remain indispensable biomedical research roche science ethic advisory group seag scientific legal reason regulatory authority require independent external expert bioethic phi healthcare company test safety efficacy new losophy offer advice counsel broad range drug animal human ethical matter include ethical approach biomedical clinical research seag follow consultative approach animal research topic perceive particularly sensitive controver decrease number animal contract sial public large order account research organisation work roche behalf decrease perspective possible compare approximately roche business report research developmentof animal mice rat overall decrease animal usage direct reflection restructure roche organisation drug portfolio change web roche pharmaceutical diagnostic pipeline wwwrochecompipeline personalise healthcare wwwrochecompersonalisedhealthcare group policy position guideline wwwrochecomresponsibilitysustainability positionspoliciesdownloadshtmguideline clincal trial safety wwwrochecomclinicaltrial wwwrochecommanagingmedicationsafety new product technology wwwrochecom innovationandtechnologie ethical standard wwwrochecomehticalstandard httpwwwrochecomaboutrochecorporategovernance codeofconducthtm genetic bioethic wwwrochecomgeneticsandbioethic animal welfare wwwrochecomanimalwelfare research development roche business report pharmaceutical pipeline noitacidni tcudorptcejorp di tcejorp sromut meh dilo tna mdm gr sromut dilo bam reh gr sromut dilos bam rfsc gr sromut dilo hni kemfic gr amonalem tem bamumilipi faroblez gr ygolocno bam kaewt gr ygolocno bam fgevgna gr sromut dilo hni laud kem far gr sromut dilos bam dc gr sromut meh dilo tna mdm gr sromut dilo hni kem gr sromut dilos rotibihni tka gr sromut dilos bam ldp gr ac etatsorp cda paet gr ac nairavo cda gr amoleym elpitlum cda gr ygolocno cda gr ygolocno cda gr lhn dna llc hni lcb gr amohpmyl mut dilos hni khc gr sromut dilo hni kip gr amonalem citatsatem cda gr l amotsalboilg hni kip gr sromut dilo hni khc gr clcsn rotibihni kla gr sromut dilo hni kip uhc eniccav recnac editpep tw uhc enil dn cbm reh atejrep gr recnac cirtsag reh atejrep gr cb ylrae reh mdt gr recnac cirtsagreh mdt gr ccb elbarepo egdevire gr llenil dnts cbm genelpirt bamuzutrano gr l enil ts crcm bamuzutrano gr l ts suomauqs non clcsn bamuzutrano gr enil ts suomauqs clcsn bamuzutrano gr enil dn amotsalboilg bamuzutrano gr sromut dilos bam rfge gr recnac dioryht yrallipap faroblez gr sromut dilo hni kip gr sromut meh dilo hni rotmkip gr sromut dilos bam lfge gr sromut meh cda dc gr sromut meh cda bdc gr sromut lailehtipe rfgereh gr recnac revil bam nacipylg gr jda cb reh nitsava gr jda cb genreh nitsava gr jda clcsn nitsava gr dionicrac ksir hgih nitsava gr enil ts amotsalboilg nitsava gr enil ts recnac nairavo nitsava gr tsiser munitalp recnac nairavo nitsava gr cb ylrae reh atejrep gr jda clcsn avecrat gr enil dr cbm reh mdt gr enil ts cbm reh mdt gr enil drdn clcsn bamuzutrano gr recnac cirtsag bamuzutrano gr llc bamuzutunibo gr despal lhn tnedicni bamuzutunibo gr lcbld bamuzutunibo gr eniltnorf lhn tnelodni bamuzutunibo gr jda amonalem faroblez gr amonalem faroblez obmoc hni kem gr noitalumrof cs lhn arehtbam gr lmt crcm nitsava gr mrof cs cb reh nitpecreh gr enil ts cbm reh atejrep gr enil ts tum rfge clcsn avecrat gr cbm detaerterp reh mdt gr ccb decnavda egdevire gr sesaesid enummiotua bam li gr ar bam li uhc sititamre cipota mic uhc sisorelcs cimetsys armetca gr sitiloc evitareclu bamuzilorte gr mehtyre supul cimetsys bamuzilatnor gr amhtsa bam emirp bamuziliuq gr ar ylrae armetca gr amhtsa ereve bamuzikirbel gr airacitru cihtapoidi cinorhc rialox gr yhtaposehtne lynevus uhc apmapg arehtbam gr noitalumrof cs ar armetca gr aij ralucitraylop armetca gr vbh tsinoga rlt gr vch enibaticirem gr vch riverponad gr vmc gr vch rivuborte gr setebaid epyt oga laud plgpig gr dvcsca bam nitcele p bamucalcni gr sesaesid cilobatem bam kscp gr dt ni sca tsop der ksir vc razatilgela gr dterpdt ni dvc der ksir vc razatilgela gr setebaid epyt razatilgela gr setebaid epyt tlgs nizoflilgofot uhc sredrosid ngoc man arbag gr msitua gatna rotpecer v gr sremiehzla hni ecab gr ainerhpozihcs aedp gr sremiehzla bamurenetnag gr sremiehzla hni boam gr noisserpe gatna rulgm gr redrosid evislupmoc evissesbo nitrepotib gr noisserpe tnatsiser xt gatna rulgm gr sremiehzla bamuzenerc gr dsa msitua nefolcabra tss smr bamuzilerco gr smpp bamuzilerco gr smotpmys gen zihcs nitrepotib gr lortnoc tpobus zihc nitrepotib gr emordny x eligarf nefolcabra tss emdovrdma vile tsus sitnecul gr yhporta cihpargoeg baf rotcafitna gr nrp gm dma sitnecul gr ailihpomeh eca uhc approve eu submit rgno roche genentech manage approve submit eu chu chugai manage submit eu sst seaside therapeutic optin submit rg mabthera brand ongoing evaluation rituxan japan fda submission rg actemra brand personalise healthcare roactemra eu project acs acute coronary syndrome mab monoclonal antibody amd agerelate macular degeneration mbc metastatic breast cancer bcc basal cell carcinoma nsclc nonsmall cell lung cancer cll chronic lymphocytic leukemia nhl nonhodgkin lymphoma cmv cytomegalovirus ppm primary progressive multiple sclerosis crc colorectal cancer ra rheumatoid arthritis cvd cardiovascular disease rm relapse multiple sclerosis dlbcl diffuse large bcell lymphoma rvo retinal vein occlusion dme diabetic macular edema sc subcutaneous hbv hepatitis b virus td type diabete hcv hepatitis c virus ygolocno noitammalfni ygolonummi ygoloriv cilobatem ralucsavoidrac lartnec suovren metsys ygolomlahthpo srehto noitartsiger iii esahp ii esahp esahp roche business report pharmaceutical pipeline pharmaceutical pipeline roche business report pipelineengfusszeilenindd ddnigneenilepipdrraehcorpharmaceutical pipeline noitacidni tcudorptcejorp di tcejorp sromut meh dilo tna mdm gr sromut dilo bam reh gr sromut dilos bam rfsc gr sromut dilo hni kemfic gr amonalem tem bamumilipi faroblez gr ygolocno bam kaewt gr ygolocno bam fgevgna gr sromut dilo hni laud kem far gr sromut dilos bam dc gr sromut meh dilo tna mdm gr sromut dilo hni kem gr sromut dilos rotibihni tka gr sromut dilos bam ldp gr ac etatsorp cda paet gr ac nairavo cda gr amoleym elpitlum cda gr ygolocno cda gr ygolocno cda gr lhn dna llc hni lcb gr amohpmyl mut dilos hni khc gr sromut dilo hni kip gr amonalem citatsatem cda gr l amotsalboilg hni kip gr sromut dilo hni khc gr clcsn rotibihni kla gr sromut dilo hni kip uhc eniccav recnac editpep tw uhc enil dn cbm reh atejrep gr recnac cirtsag reh atejrep gr cb ylrae reh mdt gr recnac cirtsagreh mdt gr ccb elbarepo egdevire gr llenil dnts cbm genelpirt bamuzutrano gr l enil ts crcm bamuzutrano gr l ts suomauqs non clcsn bamuzutrano gr enil ts suomauqs clcsn bamuzutrano gr enil dn amotsalboilg bamuzutrano gr sromut dilos bam rfge gr recnac dioryht yrallipap faroblez gr sromut dilo hni kip gr sromut meh dilo hni rotmkip gr sromut dilos bam lfge gr sromut meh cda dc gr sromut meh cda bdc gr sromut lailehtipe rfgereh gr recnac revil bam nacipylg gr jda cb reh nitsava gr jda cb genreh nitsava gr jda clcsn nitsava gr dionicrac ksir hgih nitsava gr enil ts amotsalboilg nitsava gr enil ts recnac nairavo nitsava gr tsiser munitalp recnac nairavo nitsava gr cb ylrae reh atejrep gr jda clcsn avecrat gr enil dr cbm reh mdt gr enil ts cbm reh mdt gr enil drdn clcsn bamuzutrano gr recnac cirtsag bamuzutrano gr llc bamuzutunibo gr despal lhn tnedicni bamuzutunibo gr lcbld bamuzutunibo gr eniltnorf lhn tnelodni bamuzutunibo gr jda amonalem faroblez gr amonalem faroblez obmoc hni kem gr noitalumrof cs lhn arehtbam gr lmt crcm nitsava gr mrof cs cb reh nitpecreh gr enil ts cbm reh atejrep gr enil ts tum rfge clcsn avecrat gr cbm detaerterp reh mdt gr ccb decnavda egdevire gr sesaesid enummiotua bam li gr ar bam li uhc sititamre cipota mic uhc sisorelcs cimetsys armetca gr sitiloc evitareclu bamuzilorte gr mehtyre supul cimetsys bamuzilatnor gr amhtsa bam emirp bamuziliuq gr ar ylrae armetca gr amhtsa ereve bamuzikirbel gr airacitru cihtapoidi cinorhc rialox gr yhtaposehtne lynevus uhc apmapg arehtbam gr noitalumrof cs ar armetca gr aij ralucitraylop armetca gr vbh tsinoga rlt gr vch enibaticirem gr vch riverponad gr vmc gr vch rivuborte gr setebaid epyt oga laud plgpig gr dvcsca bam nitcele p bamucalcni gr sesaesid cilobatem bam kscp gr dt ni sca tsop der ksir vc razatilgela gr dterpdt ni dvc der ksir vc razatilgela gr setebaid epyt razatilgela gr setebaid epyt tlgs nizoflilgofot uhc sredrosid ngoc man arbag gr msitua gatna rotpecer v gr sremiehzla hni ecab gr ainerhpozihcs aedp gr sremiehzla bamurenetnag gr sremiehzla hni boam gr noisserpe gatna rulgm gr redrosid evislupmoc evissesbo nitrepotib gr noisserpe tnatsiser xt gatna rulgm gr sremiehzla bamuzenerc gr dsa msitua nefolcabra tss smr bamuzilerco gr smpp bamuzilerco gr smotpmys gen zihcs nitrepotib gr lortnoc tpobus zihc nitrepotib gr emordny x eligarf nefolcabra tss emdovrdma vile tsus sitnecul gr yhporta cihpargoeg baf rotcafitna gr nrp gm dma sitnecul gr ailihpomeh eca uhc approve eu submit rgno roche genentech manage approve submit eu chu chugai manage submit eu sst seaside therapeutic optin submit rg mabthera brand ongoing evaluation rituxan japan fda submission rg actemra brand personalise healthcare roactemra eu project acs acute coronary syndrome mab monoclonal antibody amd agerelate macular degeneration mbc metastatic breast cancer bcc basal cell carcinoma nsclc nonsmall cell lung cancer cll chronic lymphocytic leukemia nhl nonhodgkin lymphoma cmv cytomegalovirus ppm primary progressive multiple sclerosis crc colorectal cancer ra rheumatoid arthritis cvd cardiovascular disease rm relapse multiple sclerosis dlbcl diffuse large bcell lymphoma rvo retinal vein occlusion dme diabetic macular edema sc subcutaneous hbv hepatitis b virus td type diabete hcv hepatitis c virus ygolocno noitammalfni ygolonummi ygoloriv cilobatem ralucsavoidrac lartnec suovren metsys ygolomlahthpo srehto noitartsiger iii esahp ii esahp esahp roche business report pharmaceutical pipeline pharmaceutical pipeline roche business report pipelineengfusszeilenindd ddnigneenilepipdrraehcorpharmaceutical division major clinical trial product indication trial phase outcome actemra rheumatoid arthritis ra adacta iv statistically significant great improve roactemra ment sign symptom measure mean change das ra patient treat actemra mono therapy vs adalimumab monotherapy actemra polyarticular juvenile idiopathic arthritis cherish iii sustain clinically meaningful improve roactemra ment actemra iv vs placebo actemra early rheumatoid arthritis function iii statistically significant great improve roactemra ment sign symptom ra great radiographic progression inhibition actemra combination methotrexate vs methotrexate actemra rheumatoid arthritis summacta iii comparable efficacy actemra sc roactemra formulation vs intravenous formulation subcutaneous formulation actemra rheumatoid arthritis brevacta iii statistically significant great improve roactemra ment sign symptom ra subcutaneous actemra sc vs placebo formulation aleglitazar reduction major cardiovascular alenephro ii renal safety study average decrease renal function event patient type diabetes patient stage chronic kidney experience acute disease type diabete rever ible coronary syndrome mild stabilise time avastin metastatic colorectal cancer ml iii significantly extend os patient receive avastin plus standard chemo therapy initial treatment continue avastin different chemotherapy cancer progress avastin platinumresistant ovarian cancer aurelia iii significantly improve pfs avastin glioblastoma avaglio iii significantly improve pfs avastin triplenegative adjuvant breast cancer beatrice iii demonstrate significant improve ment invasive diseasefree survival versus adjuvant chemotherapy dalcetrapib patient stable coronary heart daloutcome iii lack clinically meaningful efficacy disease follow acute coronary syndrome herceptin herpositive early breast cancer hera iii year herceptin confirm standard care herceptin herpositive early breast cancer hannah iii comparable efficacy subcutaneous subcutaneous formulation versus intravenous formulation formulation mabthera treatmentnave patient follicular sabrina iii minimum drug concentration confirm subcutaneous lymphoma noninferior versus iv administration formulation comparable safety antilymphoma efficacy versus iv perjeta herpositive metastatic breast cleopatra iii significantly improve pfs os cancer combination herceptin docetaxel l trastuzumab herpositive metastatic breast cancer emilia iii tdm versus lapatinib significantly improve pfs os emtansine l xeloda tdm roche business report research developmentpharmaceutical division major regulatory filing product clinical datum support filing indication dosage form country actemraroactemra cherish polyarticular jia eu actemraroactemra adacta ra dmard ir hh eu actemraroactemra summacta brevacta dmard ir tnf ir eu subcutaneous formulation musashi dmard ir japan avastin brain recurrent glioblastoma japan avastin gog icon ovarian cancer japan avastin ml metastatic colorectal cancer tml herceptin hannah herpositive earlystage breast cancer eu subcutaneous formulation lucentis harbor amd mg prn mabthera rave rituxvas granulomatosis polyangiitis gpa eu microscopic polyangiitis mpa type anca associate vasculitis mabthera sabrina sparkthera sawyer nonhodgkin lymphoma eu subcutaneous formulation perjeta cleopatra herpositive metastatic recurrent eu japan breast cancer tarceva eurtac nonsmall cell lung cancer egfr l japan tablet mg mg mg china trastuzumab emilia herpositive pretreate metastatic eu emtansine breast cancer tdm research development roche business report pharmaceutical division major regulatory approval product clinical datum support filing indication dosage form country actemra option lithe moderate severe rheumatoid arthritis adult inadequate response diseasemodifye antirheumatic drug dmard avastin ocean recurrent platinumsensitive ovarian cancer eu switzerland avastin ml metastatic colorectal cancer tml eu erivedge erivance bccshhg advanced basal cell carcinoma lucentis ride rise diabetic macular edema rituxan rate nhl fast infusion perjeta cleopatra herpositive metastatic breast cancer switzerland patients l tamiflu wp casg acute uncomplicated influenza infant week age old zelboraf brim brim braf v mutationpositive inoperable eu metastatic melanoma roche business report research developmentroche companion diagnostic market late development disease area disease drug diagnostic test technology application infectious cmv valcyte cmv viral load pcr monitoring disease hbv pegasy hbv viral load pcr monitoring antiviral hbv pegasys peginterferon hbsag levels immunoassay monitor alfab mercksp hcv pegasys peginterferon hcv viral load pcr monitor alfab mercksp hcv mericitabine rg hcv viral load pcr monitor hcv danoprevir rg hcv viral load pcr monitor hiv antiviral hiv viral load pcr monitor hiv abacavir glaxosmithkline hlab genotype pcr screen oncology breast cancer herceptin perjeta expression ihc ish selection gene amplification breast cancer tamoxifen erpr expression ihc selection hormonal therapie breast cancer trastuzumab emtansine expression ihc ish selection tdm rg gene amplification cancer compound merck p mutations microarray selection colon cancer cetuximab merck kras mutation pcr selection colon cancer panitumumab amgen kra mutation pcr selection gastric cancer herceptin expression ihc ish selection gene amplification lymphoma brentuximab vedotin cd expression ihc selection seattle genetics millenium melanoma zelboraf braf mutation pcr selection nsclc tarceva egfr mutations pcr selection gefitinib astrazeneca nsclc onartuzumab meet expression ihc selection metmab rg nsclc crizotinib pfizer alk ihc selection nsclc tg transgene muc expression ihc selection inflammation asthma lebrikizumab rg serum periostin immunoassay selection level rheumatoid mabtherarituxan rf anticcp ab immunoassay selection arthritis central nervous alzheimer disease gantenerumab rg level immunoassay selection system osteoporosis bonvivaboniva bcrosslap immunoassay monitoring bisphosphonate pnp level transplantation cellcept mpa level immunoassay monitoring project pharmaceutical company disclose confidentiality reason available market selection patient eligible firstline treatment black type market grey type development monitor monitor patient response particular treatment screening screen patient particular genetic variation hla associate hypersensitivity abacavir selection selection patient eligible particular treatment alk anaplastic lymphoma kinase anticcp antibodie cyclic citrullinate peptide braf bisoform rapidly grow fibrosarcoma oncogene cmv cytomegalovirus egfr epidermal growth factor receptor erpr estrogen receptorprogesterone receptor hbv hepatitis b virus hbsag hbv surface antigen hcv hepatitis c virus human epidermal growth factor receptor hiv human immunodeficiency virus hla human leucocyte antigen ihc immunohistochemistry ish situ hybridisation kras member ras family oncogene mpa mycophenolic acid nsclc nonsmall cell lung cancer pcr polymerase chain reaction pnp procollagen type nterminal propeptide rf rheumatoid factor sp schering plough research development roche business report diagnostic division major product launch area product description market quarter instrumentsdevice laboratorie benchmark special stain fully automate tissue stainer ww q ventana iscan ht scanner enable digital view tissue slide eu q cobas p preanalytical system decappe sort archive eu q cobas p preanalytical molecular testing system q cobas middleware software control lab workflow test result eu q solution point care cobas b blood gas analyser critical care q cobas b analyser hbac lipid monitor eu q accuchek inform ii wireless system professional glucose test q hospital diabete accuchek nano small nocode blood glucose metre q care smartview accuchek mobile nextgeneration stripfree blood glucose metre eu q japan accuchek combo insulin pumpblood glucose metre combination q life science lightcycler system realtime pcr analysis ww q seqcap ez product nextgeneration sequence prepare enriched region ww q genome seqcap ez oncology neurology panel new exome product gs flx software v enable improved longread sequence performance ww q gs flx system cedex bio ht highthroughput analyser metabolite testing cell ww q fermentation biopharmaceutical production complete ultra protease inhibitor tablet use molecular biology research ww q mycotool realtime pcr analysis kit detection mycoplasma ww q testsassay oncology immunoassay early ovarian cancer detection q p histology ihc tissue test early detection cervical disease ww q alk ihc tissue test identify patient eligible lung cancer eu q treatment crizotinib ihc tissue test detection protein tissue sample include ttf eu q lung thyroid cancer hent cancer ish tissue probe detection gene tissue sample include egfr ww q myc fgfr chromosome ki pr image analysis application antigen ki pr p q p algorithms support breast cancer diagnosis tissue sample gs gtype tetcbl gene sequence primer set leukemia research ww q kras runx infectious hcv ii immunoassay detect hepatitis c infections eu q disease hbc igm immunoassay detect hepatitis b infection q ctng pcr test detect chlamydia gonorrhoea infection q hiv v pcr dualtarget test measure hiv viral load q cmv pcr test monitor cytomegalovirus infection q metabolism accuchek aviva require users insert code chip metre ww q performa universally ongoing calibration subsequent test strip code test strip vitamin immunoassay measure vitamin q roche business report research developmentdiagnostic division key product launch plan area product description market instrumentsdevice laboratorie cobas nextgeneration modular preanalytic eu diabete accuchek insight nextgeneration insulin pump blood glucose metre eu care accuchek active nextgeneration blood glucose metre maltoseindependent test strip eu life science gs flx long amplicon software longread target sequence dna variant detection ww testsassay oncology calcitonin immunoassay support medullary thyroid cancer diagnosis monitor eu progrp immunoassay assist diagnosis small cell lung cancer eu egfr pcr test support therapy selection nonsmall cell lung cancer er ihc tissue test breast cancer diagnosis cintec plus cytology immunocytochemistry test diagnosis cervical precancer eu infectious mpx pcr nextgeneration blood screen multiplex test disease hiv hcv hbv hcv pcr nextgeneration hcv viral load test trans cyclosporin immunoassay monitor immunosuppressive drug therapy eu plantation tacrolimus sequence seqcap ez reagent kit sample preparation target nextgeneration sequence ww black type new productfirst market launch grey type new productlaunch additional market eu european union united states ww worldwide alk anaplastic lymphoma kinase cbl casita bcell lymphoma gene ctng chlamydia trachomatisneisseria gonorrhoeae egfr epidermal growth factor receptor er estrogen receptor gs genome sequencer hbv hepatitis b virus hcv hepatitis c virus human epididymis secretory protein e hiv human immunodeficiency virus ihc immunohistochemistry ish situ hybridisation kras member ras family oncogene p protein pinka pcr polymerase chain reaction progrp progastrinrelease peptide runx runtrelate transcription factor tet member tet family oncogene research development roche business report value innovation actemraroactemra relief agony childhood arthritis arthritis disease elderly rare form systemic juvenile idiopathic arthritis sjia severe systemic inflammatory disease childhood sjia affect child child sjia little energy fever enlarge liver spleen despite conventional therapy significant number child face lifethreatening complication roche actemra breakthrough treatment biological medicine approve sjia provide treatment debilitate condition make normal childhood possibility fatigue fever skin rash anemia inflammation lung inflammation heart enlarge liver spleen osteoporosis arthritis web httpwwwrochecomvalueofinnovation roactemra know actemra outside europe roche business report value innovation actemraenindd sport school activity friend fun play laura gray diagnose sjia seven year ago particularly sporty person diagnose life completely take table not anymore illness start miss bit school get lose friend not sight mind awful lot not drug m currently learn drive m go interview college option not consider ill thought time thing way way table option open actemraenindd manufacturing site roche business report manufacture procurement initiate million swiss franc investment diagnostic production penzberg germany enable rapid launch new medicine perjeta erivedge available patient day fda approval respectively develop new biotech production method technology include production process antibodydrug conjugate tdm roche business report manufacture procurement key figure manufacture site pharmaceutical diagnostic joint site employee manufacture logistic portfolio medicine test instrument manufacture procurement supply function bring inno ceutical network support broad product portfolio vative medicine diagnostic r pipeline include new oncology treatment add new patient healthcare professional worldwide stage technologies overcome technical challenge biologics global supply chain supplier manufacturer manufacture diagnostic support strong growth warehouse transportation require apply rigor sale clinical laboratory streamline part ous safety quality ethic labour health environmental network line business priority standard stateoftheart process facility ensure standard fully meet product network maintain strong commitment available reliably quality compliance continue improve pro cesse develop new capability well serve product group operation network support robust pipeline site successfully pass regulatory sale growth new product development pharmaceu inspection resolve issue internal quality audits tical diagnostic division enable roche strengthen continue reduce environmental footprint leadership oncology vitro diagnostic pharma implement new logistic strategy capital investment basel kaiseraugst switzerland approx million swiss franc project complete maintain robust capital investment programme new pharma quality control assurance building pharmaceutical diagnostic manufacture net pharma coldchain storage capacity expansion work add capacity improve production process fill line upgrade herceptin subcutaneous roche lead engineering expertise recognise formu lation fifth consecutive year facility year category ongoing project establish launch capacity highly winner operational excellence international society potent drug product upgrade fill line pharmaceutical engineering award rocephin formulation shanghai china approx million swiss franc investment highlight bud get ongoing pharma site expansion include new penzberg germany approx million swiss franc laboratory warehouse office training facility budget project initiate end complete additional manufacturing capacity expansion raw material manufacturing elecsy highly potent drug product expansion utility immunoassay complete end infrastructure complete increase compounding filling lyophilisation capacity plan roche business report manufacture procurementmanufacture site roche group mannheim kaiserb aua gse stl penzberg graz rotkreuz segrate clarecastle hillsboro vacaville south san francisco indianapolis brab nr hn bf uo rr gd legans utsunomiya oceanside tucson florence shanghai fujiedaukima toluca puerto rico singapore rio de janeiro biologics drug small molecules sterile drug solid dosage pharmaceutical substance drug substance product drug product assay diagnostic instrument diabete care reagent january pharmaceutical manufacturing manufacturing site play vital role stage product lifecycle discovery commercialisation network reduce risk supply interruption balance production pharmaceutical manufacturing network produce capacity dualregister manufacturing site medicine commercial supply clinical trial allow produce key pharmaceutical product world sophisticated biopharmaceuti facility outsource certain production con cal production plant network host approximately tract manufacturing organisation cmo gain additional global biologic production capacity make roche larg capacity increase manufacturing flexibility leverage special est manufacturer biotech sector ise technology manage cost example nere multiple cmos include manufacturer spe cialise biologic highly potent small molecule set process facility manufacture trastuzumab worldwide mammalian cell culture capacity include cmos bioplan associates inc annual report internal analysis emtansine tdm antibodydrug conjugate manufacturing procurement roche business report manufacture procurementenindd erivedge launch roche emerge market strategy work class patient local government partner establish expand local production capacity increase access medicine monday january roche received marketing distribution fda approval erivedge set remarkable co ordinated effort roche team contract manu performance facturer active pharmaceutical ingredient primary objective maintain supply reliabili ty source asia switzerland capsule produce product quality support pipeline development canada remain packaging shipment expedite launch new medicine roche artwork expert print company pharmaceutical manufacturing play decisive role work clock complete packaging design rapid launch breast cancer medicine perjeta base final wording fda approval prepare available patient day follow fda approval actual packaging roche staff site skin cancer medicine erivedge distribution day tuesday oversee packaging initial lot approval collaboration r support loaded afternoon separate truck mitigate development project new medicine include manufac damage delay wednesday morning new treatment ture investigational product approximately global safely warehouse distribution centre clinical trial involve ten thousand patient louisville kentucky fda clear shipment thursday erivedge way dis year take active step safeguard operational tributor hour reliability organisation increase inventory safety stock level ensure continuity product supply response unforeseen increase demand especially new product launch contribute total inventory increase division increase oversight supply chain include supplier cmo ensure effective response case unexpected event new business continuity process manufacturing opera tion effect biologic manufacturing antibodydrug conjugate biologics biotech manufacture challenging process take biotech level involve living cell sensitive slight change environment range factor strike new path biotech manufacturing nutrient solution timing equipment deter antibodydrug conjugate new class compound yield amount unwanted byproduct antibody substance armed toxin structure active ingredient produce promising approach long consider difficult continue expand biotech capability add new practice key challenge find right method technologie innovative approach composition chemical link antibody toxin antibodydrug conjugate adc antibody sub design scale production process stance armed toxin process step biolog ensure stability expect safety profile medi ics adc manufacturing illustrate follow cine require new process new external partner new quality specification add complexity complex biotech production process successful inherently complex production process occasionally effort manufacture organisation collaboration present challenge unprecedented biopharma r result technical dossier filing ceutical industry include onetime detection roche antibodydrug conjugate tdm eu bacterium leptospira earlystage production mid lay ground manufac cer drug mabtherarituxan importantly investigation turability medicine new class pipeline issue cooperation health authority exclude possibility clinically relevant risk patient sur roche business report manufacture procurementbiologic manufacturing process antibody small molecule nutrient solution oxygen fermentation sterile process temperature control logistics b cell line culture fermentation specific human gene insert bac production cell remove cell culture transfer progre terial mammalian cell create unique master cell bank cultured liquid growth sively large bioreactor special nutrient master cell line yield target anti medium transfer large vessel medium add unique composition body biologic drug substance mas cell multiply optimise cell line enable pro ter cell bank frozen storage duction desire antibody apurification bconjugation formulation filling packaging antibody separate biomass additional step antibodydrug conju drug substance formulate sta cell culture medium waste product gate antibody combine ble dosage form sterile liquid powder lead pure solution centrifu highly potent small molecule puri fill vial syringe pack gation purification concentration step fie concentrated shipping specific desire antibody face new potential manufacturing risk groundbreake diagnostic manufacturing work share industry experience slow expect cell growth newly scaledup pro network duction process breast cancer treatment perjeta roche diagnostic manufacturing network handle team run successful production campaign enable aspect production procurement logistic timely launch commit postmarkete production industryleade ivd product portfolio include data review fda demonstrate resolution different stateoftheart instrument perform problem maintain future supply test require reagent kit agent control component consumable pipette cuvette manufacture procurement roche business report biotechenindd bit steel material analytical service penzberg germany plastic juice new closed site burgdorf switzerland dna testing system additionally modify manufacturing network base change product portfolio diagnostic roche new midhighvolume testing platform cobas business close roche apply science reykjavik expect bring exceptional iceland site transfer production sequence capture level automation throughput costefficiency device madison initiate project molecular testing blood screening lab add streamline diabetes care operation reduce cost considerable complexity development manufacture business unit adapt tough market environment blueprint pilot production roche production continue pursue longterm team background biology biochemistry engi initiative aim sustainable high performance neere start march set process establish continuous improvement culture met transform steel plastic software juice new ric manufacturing quality performance right time system include variety test kit closely coordinate methodology tool place ensure effort include manufacture site rotkreuz switzer robust production process design quality manu land branchburg penzberg germany r facturability positive trend site pleasanton multiple global external supplier continue optimise manufacturing capacity asset manage complexity team work ensure management initiate major capital investment pro exact quality control build production pro ject site penzberg germany cesse high quality standard apply inter start new initiative expect generate nally supplier site significant saving year supply chain excel lence initiative enhance reliable costeffective december pilot molecular analyser supply product optimise inventory level deliver customer field test procurement excellence initiative ensure strategic source improved supplier management include new supplier performance measurement tool manufacture majority instrument test house allow maintain cost quality advantage quality compliance leverage proprietary technology special expertise use external manufacturer access unique override goal ensure person receive technology control cost production safe medicine reliable diagnostic test result achieve handheld blood glucose metre large work station consum apply rigorous standard roche able increase number subassemblie product manufacture source ensure quality management system conform law performance regulation recent norm standard achieve goal save cost maintain include cgmp ich iso supply product meet division abovemarket sale growth example deliver million test harmonise enhance quality system kit roche elecsys immunoassay product line highly roche continue global harmonisation quality automate blood testing laboratory worldwide alltime management system pharmaceutical division high level output major achievement business establish new system global standard support launch major diagnostic product area quality management risk management key market table preventive corrective action local implementation continue transform network line business priority operational excellence programme current good manufacturing practice cgmp international confe launch late consolidated chemical raw rence harmonisation technical requirement registration pharmaceutical human use ich international organization standardization iso roche business report manufacturing procurementongoe diagnostic division effort harmonise green warehouse multiple quality system complete yearend harmonisation expect drive compliance end pharma warehouse mannheim efficiency instance enhance manufacturing germany refrigerate normal storage externally organisation ability manage quality performance rate stateoftheart energy efficiency build exchange good practice network warehouse constantly optimise include highly sophisticated environmentally friendly design fea assure compliance ture process example energy consumption regulatory authority conduct safety quality minimise air conditioning heating system inspection roche group site pharmaceu orient working hour window shutter reduce sunlight tical site diagnostic majority inspec radiation facility feature heat tion result critical observation recovery system special gate insulation packaging waste recycle directly warehouse pallet collaboration authority roche pharma resolve greatly reduce waste draw role model quality concern mircera xenical production strive kind energy efficiency discover internal audit interrupt warehouse roche develop good practice action supply product hold release catalogue roll globally roche diagnostic continue track propose revision vitro diagnostic directive eu pre pare new fda rule unique device identification reduce environmental impact standardise code device plan implement new green logistic area increase focus supply packaging design barcode warehousing procedure chain seek systematically reduce air emission accordance final rule energy consumption waste contribute groupwide effort reduce environmental impact collaborate health authority reduce use airfreight implement seafreight roche continue collaborate authority provide lane supply hub germany saudi arabia expertise include input guidance document south africa singapore hong kong israel france propose regulation law take lead role change result reduction co emission implement quality design approach include approximately tonne strong focus risk management maximise quality performance design production process perjeta additionally address energy consumption waste represent fda submission industry bio warehouse reuse recycling packaging material technologically manufacture drug base principle establish goal calculate monitor achieve ment foster employee engagement increase partner choice industry input medi awareness training include example implement cine companion diagnostic cdx work directly new elearning tool september fda shape regulatory landscape cdx roche instance participate meeting information safety security health fda regulator cdx environment follow supply chain management commitment quality innovation sustainability extend supply chain respond quickly market development ensure reliable product sup ply reduce environmental footprint maintain highly integrate responsive global supply chain division manufacture procurement roche business report procurement sustainability principle supplier code conduct incorporate principle pharmaceutical supply chain procurement team work closely business unit initiative psci value chain seek innovative purchasing solution help achieve goal generate cost saving aligning building capability reinveste business create maximum value apply implement new common standard measure total cost ownership concept holistic longterm report procurement saving continue drive major view benefit cost purchase decision joint source project research study temporary labour production relate purchase credit card busi procurement organise division procurement poli ness travel pursue globally align approach cie process system largevolume spend retain local execution realise substantial saving risk management closely align group line business target negotiate key contract objective ensure sustainable performance adher google provide employee worldwide new uni ence good practice industry code roche example form cloudbase email calendar expect require supplier commit activity enhance connectivity collaboration procurement value chain support diverse need right supplier partnership procurement strategic partnering value chain research development manufacture commercial need lab equipment raw material reliable supplier logistics service marketing service service invent develop provider high quality product successful launch new drug diagnostic include supply patient customer commerciali sation product service run clinical trial lifecycle exam supplier diversity access medicine make event ple key partnership small diverse contracting indian manu new approach manage con supplier own business local facturer local filling packaging gresse meeting event partner community specific rd supply herceptin mabthera great transparency partici ship improve access medicine pation prioritisation event initiative value outsource india involve transfer significant tool plan book development new contracting process knowhow enable substantial cost saving model outsource entire clinical programme external partner roche business report manufacture procurement procurementenindd expect generate value efficiency audit protocol supplier audit continue enhance organisational structure capa protocol independent auditor bilitie emerge market enable proactive systematic management local spending example majority supplier audit meet exceed roche diagnostic start procurement office singa minimum requirement decide stop business pore beginning support asiapacific supplier meet minimum standard region roche pharma roll nextgeneration pro main finding direct spend area relate industrial curement system china hygiene safety design finding service provider enhance relationship management oversight sup occur primarily social ethic area plier new procurement excellence programme diagnostic frame pharmaceutical focus supply reliability web develop people exchange knowledge new global learning development platform biotech production wwwrochecombiotechnologyproduction pharmaceutical supply chain initiative pharma procurement catalogue customisable wwwpharmaceuticalsupplychainorg course access internal external resource supplier engagement wwwrochecomstakeholderengagement supplier code conduct wwwrochecom rochesuppliercodeofconductpdf procurement value chain engage supplier seek build mutually beneficial sustainable relation support diverse need right supplier partnership ship supplier actively engage collaborate manage performance risk ensure quality compliance reduce combined environmental footprint promote innovation account different business need value chain illustration june roche launch industry supplier rela tionship centre south san francisco roche employee colocate representative key sup plier dedicated find innovative way generate mutual benefit roll new elearne module help supplier increase knowledge employ procurement strategic partnering value chain ee sustainability roche supplier code conduct industry standard supplier day shanghai china research development manufacturing commercial participant provide opportunity supplier learn sustainability audits need lab equipment raw material reliable supplier logistics service marketing service partnership institute supply chain management service invent develop provider high quality product successful launch diversity alliance science roche engage new drug diagnostic include supply patient customer commerciali sation product programme provide opportunity innovative com service run clinical trial lifecycle petitive diverse supplier exam supplier diversity access medicine make event monitor compliance ple key partnership small diverse contracting indian manu new approach manage con ensure compliance roche industry code supplier own business local facturer local filling packaging gresse meeting event standard conduct supplier audits partner community specific rd supply herceptin mabthera great transparency partici ship improve access medicine pation prioritisation event region include followup audits initiative value outsource india involves transfer significant tool plan book direct spend area good directly pro development new contracting process knowhow enable substantial cost saving duction model outsource entire clinical service provider programme external partner roche collaborate healthcare company psci develop unified joint sustainability manufacture procurement roche business report procurementenindd value innovation chest pain approximately emergency room consul tation patients heart attack symptom million patient see emergency department year chest pain rapid accurate diagnosis early risk assess ment critical patient arrive troponin test high troponin heart attack likely initiate treatment low troponin consider rule heart attack available st twostage testing diagnose nd market heart attack release patient consider ecg information clinical hr hr hrs hrs hrs hrs hrs symptom hospital highsensitive test time second test new highsensitive test allow reduce time reduce hour second test hour ongoing clinical study take cardiac testing level study ongoing enhance use medical value troponin testing clinical practice emergency setting instance regular checkup patient risk onehour diagnosis heart patient monitor major attack study evaluate surgery study assess chest pain patient use troponin test securely diagnose troponin high patient monitor major noncardiac sur sensitive test admission final gery million adult worldwide undergo test hour trial help patient major noncardiac surgery year pressure emergency department million die day regular troponin enable rapid transfer specialise treatment testing help physician identify patient early discharge trapidami study start risk detect cardiac injury wise unnoticed cause death vision study start web httpwwwrochecomvalueofinnovation roche business report value innovation cardiacmarkersenindd highsensitivity cardiac test precise testing life death decision diagnose heart attack patient challenging problem face doctor hospital emergency department heart attack require immediate intervention like heart catheterisation coronary bypass surgery blood test accurately determine patient heart attack literally mean difference life death year ago physician rely symptom electrocardiogram ecg miss heart attack roche develop elecsys troponin highsensitive test detect presence troponin protein release blood stream heart attack troponin test reliable indicator heart attack gold standard worldwide cardiac critical care heart attack blood flow block muscle cell die troponin release heart attack cause inter ruption blood supply part heart cause heart cell die commonly blockage coro nary artery follow rupture substance call arterial plaque inner wall arteries prof christian mller cardiologist head outcome research university hospital basel highsensitivity cardiac troponin indispensable test early diagnosis heart attack enable detect small heart attack miss use conventional test critical help allocation resource emergency department identify patient cardiac disease early focus right resource patient outset cardiacmarkersenindd patient receive treatment topselle roche medicine roche business report marketing distribution customise innovative market solution increase access medicine launch educational initiative asian country promote excellence testing herpositive breast cancer start programme peruvian government provide cancer care access million country poor citizen roche business report marketing distribution key figure core marketing distribution expenditure roche group millions chf cer sales pharmaceuticals millions chf cer sale diagnostic millions chf cer sale constant exchange rate average fullyear employee roche group pharmaceutical diagnostic tailor market strategy sustain medical innovation order meet medical need help address mount pressure healthcare budget healthcare system world vary greatly region sophisticated new medicine diagnostic priority diagnostic division support devel test readily available healthcare infra opment reimbursement programme identify estab structure limit basic medical care luxury lish evidencebase payment coverage decision access good medical care depend different provide effective accurate assessment analytical factor include income level availability medical profes clinical validity advance molecular diagnostic test sional political commitment common health particular diagnostic division united states capi care authority intense budget pressure need talise reimbursement programme prove sustainable healthcare solution pressure drive result market innovative way bring effec tive medicine patient affordable cost initiative roche heavily involved co found green park collaborative international roche focus ensure product demon group explore feasibility develop guideline strate real benefit patient represent mean design clinical study meet need hta organisa ingful expenditure healthcare authority tion payer aim programme involve increasingly develop way bring value payer early improve relevance clinical research healthcare system enable people possible accelerate patient access new drug technology benefit medicine actively participate joint initiative demonstrate value pharmaceutical industry santsuisse association work closely healthcare authority insurer swiss health insurer stakeholder develop basic payer demonstrate value product service principle future htas switzerland establish turn gain appropriate reimbursement market consensus valuation health technology access collaborate authority policy objective improve quality transparency health maker actively contribute health technology assess care system increase efficiency reduce ment hta systematically evaluate cost cost project trigger broad interest outside benefit innovative medicine diagnostic order switzerland example stakeholder typically guide efficient effective use aim conflict interest come roche business report market distributionaccess healthcare programme highlight child support seven african country india infant test hiv amplicare initiative monitoring diabetes partnership novo nordisks change diabete child programme country roche file enforce patent laboratory technician train hiv diagnostic medicine partnership president emergency plan aid relief right solution right market system majority population turn situation view size fit come bring different approach disparity work product market develop right solution government support public healthcare access individual market require significant longterm commitment find solution bring medicine need understand need challenge country pilot differential pricing programme partnership healthcare system decentralise busi governmental organisation include provide ness model empower local management team work diagnostic test education package solution closely healthcare provider determine good appropriate individual country need example customise solution appropriate local market condition south africa work government enable mabthera treatment nonhodgkin lym phoma reimburse public healthcare system innovative pricing model second brand tailor approach local healthcare system emerge market invest locally develop reimbursement arrangement value partnership manufacture finish product uniform pricing structure example pro order improve access medicine underserve gramme place differentiate price medical value market segment product commercialise drug vary depend indication different brand name come slightly different treat pay performance pay form example vial syringe approach ment model example italy refund give support longterm growth strategy market disease progress early anticipate accord provide affordable solution public healthcare e pivotal trial programme model authoritie successful number market western europe example india roche emerge market key roche growth strat develop second brand cancer drug herceptin egy economic growth necessarily match improve mabtherarituxan step wide initiative ment healthcare infrastructure funding implement manufacture roche product collabora market strike difference access tion local partner stateoftheart facility medical care high income private sector people biologic manufacture second brand strategy drive access quality healthcare public health growth india partnership government marketing distribution roche business report help patient access increase access medicine patient poverty new medicine line example second brand egypt launch second brand hepatitis c drug public focus enrol patient clinical trial obtain healthcare market people datum require enable regulatory reimbursement treat receive authority review decide new treatment medicine market reimburse approval regulatory authority way medicine patient assistance programme broadly available patient use supervision recognise patient develop qualified healthcare professional doctor country afford treatment insur ance able pay treatment fully recognise possible cover individual insurance plan mitigate barrier patient receive benefit new medicine healthcare roche provide patient assistance programme enrol ongoing clinical trial possible assist underinsured uninsured clinical trial potential disease setting available access medicine united states genentech specific circumstance roche provide patient access solution help underinsured preapproval access paa unapproved investiga uninsured patient access appropriate medicine tional medicine outside clinical trial process genentech access care foundation provide free medi approve regulatory authority cine patient uninsured meet specific expand access program set financial medical criterion preapproval safety study eu country compassionate use china launch patient assistance pro gramme herceptin breast cancer medicine treatment cost reduce increase number people benefit drug public healthcare system infrastructure development area world healthcare infrastructure rudi improve breast cancer mentary significant challenge exist improve diagnosis asia limit fiscal constraint basic level critical shortage medical professional health roche launch sphere scientific partnership facility low awareness cause symptom test excellence programme asiapacific prevention treatment disease poor electricity educational initiative promote facilitate excellence supply hospital equipment run help resolve testing breast cancer herpositive breast cancer issue roche collaborate local stakeholder particularly aggressive form cancer require government international health organisation support timely accurate diagnosis education development healthcare infrastructure improve availability medicine provide diagnostic programme currently run market asia test peru example roche begin programme china korea taiwan hong kong indonesia philippine government provide cancer care access mil thailand vietnam malaysia lion poor citizen provide diagnostic pricing plan laboratorie pathologist surgeon medicine support education infrastructure technician educate initiative development sphere aim increase accuracy reliability algeria roche support initiative bring breast testing asia turn increase chance cure cer screen woman rural area mammography disease programme look help centre far fully equip truck spheretraine centre monitor improve testing locally refer mamobile train nurse parameter build regional database radiologist travel mainly southern sahara status breast gastric cancer mammogram local woman programme pilot biskra southeast country screen roche business report marketing distributiona woman day aim screen bespoke solution woman eligible province possible chinese lab programme roll area middle east roche diagnostic china clinical lab business continue grow time customer satisfaction rate chinese ivd market equipment sale track customer satisfaction regular interval usually hospital city ivd business annually biannually benchmarke performance benefit considerable investment country peer industry average survey conduct government multibillion dollar investment roche party gauge customer satisfaction healthcare infrastructure representative knowledge helpfulness visit effectiveness medical support clinical datum dis ability offer broad range modular instrument tribution quality information educa desktop solution largescale equipment key tional material addition diagnostic division look growth chinese customer primarily expand delivery times service technical support level lab step step analyse feedback identify appropriate equally important broad array test run communication channel establish sale marketing instrument include immunoassay plan set target area identify represent fastestgrowe segment important customer opportunity develop flexible sale model distributor improve performance ensure distributor easy access instrument addition service team control pre post sales service ensure high customer satisfaction level web market strategy secure product wwwrochecomproduct market lead position growth diagnostic assess value product pricing wwwrochecom medicalvaluepatentsandprice china access healthcare overview wwwrochecom accesstohealthcare genentech access solution wwwgenentechaccesssolutionscom list patient group support wwwrochecompatientgroup responsible marketing wwwrochecom businessintegrityandresponsiblemarkete roche policy guideline position wwwrochecom positionspoliciesdownloadshtm marketing distribution roche business report value innovation accurate diagnosis personalise healthcare focus healthcare budget target treatment rapid accurate diagnosis fundamental successful treatment cancer identify patient likely benefit personalise treatment improve patient outcome save time money well spend breast cancer example case aggressive type know herpositive treat kind breast cancer specifically hertargete therapy patient increase risk cancer spread general therapy limit effect impact roche develop suite test provide rapid reliable result enable informed decision hertargete treatment patient dr alan sokolow medical director health insurance company accelushealth personalise healthcare dia gnostic clear advantage significantly improve health reduce healthcare cost like physician adopt approach recognition payer realise new test therapy deliver value offer quality waste quality testing critical b ihc test dual ish test early step patient confront breast mark protein line show ratio gene cancer usually biopsy take small test chromosome secondline suspect tumour tissue analyse testing case equivocal ihc fully tap potential personalise healthcare test result key minimise risk false test result roche test show inde pendent assessment accurate reliable automate processing sophi sticate tissue stain instrument help save cost lab reduce possibility human error ensure delivery patient result quickly possible literally overnight web httpwwwrochecomvalueofinnovation accord nordiqc test comparable superiority dual ish assay prove pathway antiherneu b roches b ihc test loftin ir et al multisite clinical study rabbit monoclonal primary anti poor borderline result mayr et al show reduce inaccuracy rate compare body lead competitive ihc assay produce competitive fish assay false result ventana b test inform dual ish dna diagnose patient correctly probe cocktail roche business report value innovation hertestenindd hernegative patient different treatment course unnecessary therapy patient inaccurate test result receive inappropriate treatment herpositive patient eligible treatment dramatically improve chance survival cure resource save cost test inaccurate test result jeopardise benefit resource optimally create unneccessary cost allocate hertestenindd swiss franc contribute patient organisation roche business report responsible business launch roche compliance pulse check evaluate progress noncompliance case host think tank schizophrenia well understand need patient carer work regulatory authority develop strong framework biosimilar approval roche business report responsible business key figure contribution healthcare institution million chf contribution patient organisation millions chf integrity sustainability aspect business roche require external business partner adhere world large healthcare company roche high standard employee local manager maintain high standard business ethic integ responsible monitoring report compliance rity respond quickly noncompliant behaviour supplier code conduct clearly outline expectation commitment responsible business behaviour go supplier chief compliance officer serve con strict legal compliance demand conduct tact person external stakeholder issue relate ethical open form basis sustainable implementation compliance roche group business create longterm value stakeholders code conduct run business way profitable roche tolerate violation code conduct responsible committed triple line prin noncompliance allegation confirm line manager ciple drive social environmental performance request immediate corrective measure diligence financial performance impose adequate sanction employee warn sustainability management apply materiality framework letter bonus cut termination employment contract continuously look positive impact sustain business partner behave appropriately ability initiative business hesitate terminate relationship employee report concern line man code conduct ager local compliance officer chief compliance officer alternatively report noncompliance issue roche group code conduct guide employee anonymously roche speakup line accessible business behaviour worldwide cover topic cor country language tolerate porate personal integrity social responsibility compli retaliation employee raise compliance ance management employee complete mandatory training concern good faith allege violation code ensure understand code conduct include conduct report speakup line find help advice raise compliance concern business practice behaviour addition local compliance officer report material business ethic incident chief compliance officer roche develop compliance programme business ethic report area incorporate key element good practice compliance fraud theft violation good marketing practice embezzle program clear purpose embed compliance ment false record conflict interest discrimination daytoday business operation convince harassment allegation carefully investigate result compliance closely link good leadership leader e termination employment contract account oblige foster environment trust encourage unethical behaviour agreement business employee speak measure business partner reason result ability manage team roche business report responsible businesscompliance initiative contribution healthcare institution launch supplementary initiative includ total million swiss franc e roche compliance pulse check set healthcare compliance council hcc compliance pulse education check tool enable local management employee healthcare professional compliance officer assess progress handle education detection noncompliance case hcc head general public chief compliance officer bring compliance representative pharmaceutical diagnostic research division compliance expert region affiliate hcc fulfils coordination function intend ensure common interpretation healthcare provi code conduct industry countryspecific sion code conduct support consistent marketing code guideline good practice addition implementation roche compliance programme roche use groupwide questionnaire help local manag group er assess compliance awareness responsible sale marketing practice general manager sunshine act regulation sign declaration assurance acknowledging strengthen good business practice compliance practice put place new global webbase system process contribute roche ability comply new regula goal enable healthcare professional deci tory transparency requirement like physician payment sion independently base relevant datum available sunshine act similar disclosure regulation deliver great medical benefit patient europe world system enable roche collect contribution healthcare professional education healthcare professional global function crossborder engagement roche dedicated support education healthcare prepare roche fully compliant sunshine act professional high quality programme regulation aim improve knowledge disease product area particular expertise education doctor nurse healthcare official care stakeholder engagement giver main objective ensure good care possible patient roche believe open constructive interaction patient healthcare professional improve ability end broad range educational activity fit treatment patient publication education training material host support medical congress focus pharmaceutical industry govern strict regulation different aspect medical care include new guideline sale marketing product roche standing disease different treatment option safety rigorous internal process place ensure concern product use healthcare general diagnos employee adhere law regulation industry code tic establish testing laboratory train lab technician conduct support good marketing practice code run pathology educational course set quality control conduct set standard adhere regulatory programme compliance interact engage healthcare professional interaction healthcare professional activity seek exchange scientific infor aim exchange scientific information well use mation knowledge roche product service interaction improve understand emerge clinical datum relate base standard integrity fair remuneration ser therapie investigation vice commit benchmarking achievement increase clinical provider payer understand good practice include transparent report good treatment option include safety efficacy vari ous therapy patient continuously train staff interact healthcare pro help clinician communicate medical information effec fessional increase awareness understand tively patient caregiver responsible business roche business report patient support example contribution patient organisation total million swiss franc wwwaccuchekconnectcom offer tool resource live diabete educational grant clinical evidence case study healthcare professional workshop seminar wwwbonivacom offer osteoporosis prevention meeting care patient boniva myboniva program treatment adherence project provide resource help compliance wwwherceptincom offer guidance disease awareness general education treat herceptin herpositive breast gas tric cancer information financial support resource wwwcancerchampionprogramorg offer support advice cancer patient responsible use medicine priority area website product mechanism remind patient medication provide access train nurse information live disease medical effect education enhance patient care provide course different format digital additionally roche operate counsel centre tele classroom networkbase hospital lab environment phone help line coordinate service improve treatment exist medical event example year compliance rehabilitation actively engage organise symposium virtual medical conference patient patient group gain insight challenge connect annual meeting american society face patient family clinical oncology asco asco world large clinical oncology event attract thousand healthcare pro example host think tank schizophrenia fessional support continue medical patient caregiver europe idea learn education symposium clinical management patient issue challenge face caregiver acute coronary syndrome type diabete european patient order shape planning strategy society cardiology congress recommendation eu policy maker roche new medicine bitopertin development address negative parallel kind activity roche provide grant symptom schizophrenia independent medical education education generally provide independent organisation commu transparency essential interaction patient nity hospital academic centre society association roche publicly declare patient group relationship example available unrestricted educational describe activity rochecom acknowledge grant enable independent scientific presentation financial nonfinancial support recommend rheumatic disease european league rheuma european federation pharmaceutical industry asso tism eular congress ciation efpia patient caregiver patient group healthcare education awareness important patient safety patient wellbee proper medical diagnosis treatment mind produce newsletter magazine product effective safe publication aim help people healthy shelf life roche continuously monitor choice prevent disease increase general awareness safety drug time evaluate clinical study disease organise disease awareness campaign withdrawal market association patient group local hospital con duct screen programme like algeria breast drug safety committee responsible drug safety cancer p governance proactively ensure patient safety roche business report responsible businessour employee require immediately report issue support authority effort actively pursue relate safety quality medicine quality prosecute counterfeiter distributor process system regularly audit internally inspect major regulatory authority roche addition implement internal anticounterfeit ing measure design packaging labelling pharmaceutical proactive safety management plan product recommend buy prescriptiononly medicine support qualified physician monitor overall exclusively trust source doctor authorise safety risk management plan place review pharmacy approve regulatory authority adverse event store global database review qualified physician roche participate industry governmental report promptly appropriate regulatory authority effort safeguard medicine supply chain protect require link roche product evaluate patient example work closely eu com benefit medicine outweigh risk mission development falsify medicine directive maintain strict product recall procedure ensure aim stop counterfeit medicine reach patient withdraw product rapidly quality safety introduce harmonised paneuropean safety control problem arise measure include unique product identification number tamperevident packaging restriction repackage despite extensive safeguard end follow strongly advocate measure increase public e internal quality review roche identify unreport awareness counterfeit ed potential miss adverse event patient assistance program immediately launch investigation support anticounterfeit organisation pharma notify health authority january ceutical security institute international federation initiate comprehensive corrective action plan pharmaceutical manufacturer association european federation pharmaceutical industry associa addition routine inspection uk regulatory authority tion cooperate company january february identify finding roche safety relate process roche fully cooperate roche act immediately potential counterfeit health authority clarify observation find product bring attention include inform case implement corrective preventative health authority respective country counter action agreement health authority base roche feit find assessment date impact safety profile product find european medicine internally draw number department skill agency health authority confirm medi fight counterfeit roche establish roche anti cine remain authorised change treatment counterfeiting commission consist member advice patient healthcare professional correc affected department heavily involve coordina tive preventative action result inspection tion anticounterfeiting activity inve complete newly define process imple tigative staff shanghai china highrisk region mente routine practice latin america middle east counterfeit biosimilar counterfeit product look identical authentic version similar biological medicinal product biosimilar make difficult detect especially patient coun reality market unlike generic terfeit medicine cause illness death chemically synthesise medicine complexity bio contain harmful ingredient deprive patient logical production process mean copycat product proper treatment identical original medicine present new set safety competitive challenge national health authority custom police intergovernman pharmaceutical industry tal agency international organisation world health organization primary responsibility view biosimilar meet rigorous prevention control counterfeit roche collaborate regulatory quality standard innovator original organisation help prevent counterfeit biological medical product order ensure patient safety responsible business roche business report protect patient safety biosimilar regulatory pathway biosimilar pathway biosimilar pathway development mean product intend copy license risk crisis management mono clonal antibody demonstrate similar quality non clinical property clinical safety efficacy headto risk management policy set approach identi head study product describe fye manage report internal external risk intend copy biologic monoclonal antibody use stakeholder feedback help manage social environ biosimilar mental economic risk roche active support development strong consistent methodology process routinely regulatory framework approval biosimilar perform risk assessment level organisation engage discussion primarily association group risk report cover material risk annually emerge biopharmaceutical enterprise biotech discuss corporate executive committee nology industry association america international audit committee board director regularly federation pharmaceutical manufacturer associa update risk management process raise awareness tion clear guideline implement understand risk roche group fda european medicines agency world health organization number key emerge market group risk management team provide advisory service india south africa latin america site affiliate project product team monitor risk pattern specialist area social medium security compliance sustainability elearne programme class roche business report responsible businessroom training workshop place improve political donation stand risk help employee manage appropri ately roche remain independent political affiliation additionally establish incident management team switzerland roche spend million swiss franc roche group ensure act quickly contribution donation organisation safe emergency team regularly rehearse different crisis guard interest include payment interpharma scenario alert escalation procedure continue economiesuisse scienceindustrie swissholding strengthen business continuity management bcm chambers commerce financial assistance trade union ensure site respond effectively catastrophic donation political party cantonal federal event business continuity management task force level donation political party lowdoubledigit establish group bcm policy guideline thousand franc sum overall total contri template facilitate consistent align local impleman bution donation tation groupwide rollout new bcm framework sure roche operation resilient capable employee personal political contri absorb important disruption bution roche good government committee genentech political action committee genenpac voluntary political action committee employee contribute public policy donate dollar political campaign committee roche actively engage consultation government industry body regulatory authority stakeholder issue affect pharmaceutical medical device web industry objective help develop law regulation policy public health shape debate roche group code conduct wwwrochecomcodeofconduct roche supplier code conduct wwwrochecom area priority include work eu clini rochesuppliercodeofconductpdf cal trial regulation objective support harmo position policy guideline wwwrochecom positionspoliciesdownloadshtm nised streamline framework clinical trial roche position respect human right wwwrochecom facilitation multinational trial addition responsibilityemployeeshumanrightshtm risk management compliance wwwrochecom actively promote discussion issue parallel riskmanagementandcompliance trade reference pricing detrimental consequence responsible marketing wwwrochecom businessintegrityandresponsiblemarkete lowprice eu country aim raise issue un list patient group support wwwrochecompatientgroup equal access highvalue medicine endorse princi roche clinical trial patient safety wwwrochecomclinicaltrial wwwrochecommanagingmedicationsafety ple differential pricing way enable well access counterfeit wwwrochecomcounterfeiting pharmaceutical citizen europe area con patent biosimilar wwwrochecompatents stakeholder engagement wwwrochecomstakeholderengagement sultation eu include new rule medical device ivds datum privacy personalise healthcare respect human right roche fully support implement united nations ruggie framework protect respect remedy design prevent address risk adverse impact human right link business activity corporate sustainability committee assess risk opportunity relate roche business well implement un framework committee subsequently establish roche position respect human right endorse corporate executive committee use internal external communication responsible business roche business report value innovation working insurance industry china improve health insurance coverage cancer patient cancer major killer world healthcare coverage cancer treatment country patchy case nonexistent roche work private insurer clinic asia latin america europe help well serve cancer sufferer like country china face sharp increase cancer rate cancer killer urban area second lead cause death country age population pollution heavy smoking adoption western lifestyle mean cancer remain major health issue china foreseeable future currently cancer patient china pay cancer treatment sell cover cost recent year roche start work closely insurance company help establish insurance policy million policy cover cancer treatment cost sell china ryan bi taikang life insurance co ltd customer need diagnose cancer follow way pay cancer treatment insurance money come second treatment plan important area insurance company lack knowledge roche board exactly help need green channel access step green chan nel access plan offer benefit people insurance policy green channel access allow insured see quick relevant doctor key selling point insurer generate revenue hospital roche bring insurer hospital order achieve roche business report value innovation chinaenindd challenge support roche insurance industry national overview cancer treatment cost analyse treatment cost lack gathering help insurance company datum datum difficult calculate risk pricing policy price policy sale force fully recognise importance cancer coverage provide lecture cancer depth educate understand insurance company roll cancer awareness value understand campaign benefit innovative treatment patient insurance company share information know knowledge guiding constitute good client good cancer gap cancer treatment treatment web httpwwwrochecomvalueofinnovation chinaenindd employee worldwide fulltime equivalent roche business report people establish seven leadership commitment standard behaviour expect roche leader introduce innovative employee benefit programme support talent retention host diversity summit leader address role leader create inclusive diverse workplace roche business report people key figure women key position track reach goal roche employee worldwide fulltime equivalentsfte employee fte function europe marketing distribution north america research development asia manufacturing logistics latin america servicing australia general administration africa total total employee fte operating unit employee contract type roche pharmaceutical regular fte chugai fix term fte diagnostic division time headcount time headcount total fulltime equivalent fte reflect actual working time parttime employee example parttime employee work result equivalent fte versus employee headcount people drive business dedication determination support system encourage collaboration people translate innovation science well people need develop personally profes live patient enable roche remain forefront sionally healthcare industry century embrace diversity culture people roche group recognise employee engage key matter share fundamental value deliver high standard great level integrity courage passion innovation way track engagement use employee survey companywide survey roche group global employee opinion survey geo build great workplace conduct employee engagement line industry average strategic goal roche commit constantly strengthen maintain reach employee engagement level end e excellent workplace foster innovation followup employee survey conduct early go offer attractive compensation benefit well understand journey excellent workplace critical success wellbee people strive build work environment roche business report peoplein response geo employee feedback leadership commitment corporate executive committee cec establish employee engagement taskforce include leadership believe employee deserve great leader work stream gather input expect follow leader regardless roche leader develop leadership commitment area work level responsibility commitment outline behaviour expect roche leader serve common standard people lead day strive lead example consistently demon ership level company strate roche value integrity courage passion roll globally integrate key hr pro mean cesse recruitment development performance genuine interest people management additionally taskforce identify way listen carefully tell truth explain improve visibility transparency employee career empower trust people decision development learn development p discover develop potential people strive excellence extraordinary result taskforce back global programme recognise set priority simplify work individual timely meaningful way contribution congratulate people job locally culturally tailor recognition award range simple thank formal reward pro gramme element pilot south san francisco pharma development globally worldwide imple employer choice mentation broad programme anticipate roche consistently recognise globally employer choice reflect commitment foster maintain introduce global wellbeing programme collaborative working environment embody roche build align exist local initiative core value integrity courage passion table ensure employee world access highlight award earn roche wellbeing initiative continue identify implement activity initiative group local level address employee engagement key award recognition switzerland employer rank st crf institute roche pharma switzerland fortune good company work th consecutive year genentech south san francisco science employer rank rd genentech south san francisco science employer rank th roche germany employer certify crf institute roche pharma germany total equality award winner total equality deutschland association roche diagnostic roche pharma germany china employer certify china employers crf institute roche diagnostic shanghai limited denmark good workplace st place great place work institute roche denmark good employer slovakia rank nd good employer study aonhewitt roche slovakia desire employer rank th antal international roche pharma roche diagnostic poland universum ideal employer rank nd employer natural science roche switzerland universum ideal employer rank th employer natural science roche germany great place work rank st great place work institute roche brazil exclude genentech people roche business report roche talent pool uk flexible benefit include health insurance vacation day buy sell preparation job vacancy fill internally bike purchase personal fitness taleo recruitment platform rochehoste career website country draw million attract good scientific talent collaborat visit compare million receive ing directly academia postdoctoral pro application post vacancy register gramme research early development gre new candidate database job seeker pre gre postdoctoral programme interested roche employee position whilst pre postdoc project involve collaboration outstanding academic group europe switzerland china japan generally employer pay close attention attract retain talent change need expectation workforce actively promote flexible working model employee attract retain highly skilled passionate moti encourage use late technology allow embed vate people helping perform consistently high roche mainstream culture level vital ability innovate deliver superior business performance attract employee staff rate commit recruit talent increase diversity workforce recognise new hire come challenge marketplace include stiff internal staffing rate competition good people science medicine espe external staffing rate cially emerge market india brazil china retain employee turnover respond market condition continuously adapt ing adopt innovative talent acquisition strategy reflect good practice inhouse recruitment team total talent scout employ late social medium tool europe retain traditional route recruitment business north america schools university connect engage talent asia ensure know opportunity available work latin america ing roche effectiveness effort recog australia nise externally roche receive potential africa park award good online talent communicator uk asia europe rank second online reason leave recruitment technique emerge market innovative approach involve adapt employeeinitiate ing enhance employee benefit programme meet local employerinitiate market need example neutral china turnover rate high country start phasein new flexible benefit include cancer insurance pharma employee family learn career development singapore programme include elderly care nursing home expense option call staycare employee encourage expand expertise employee use flexible benefit fund pursue professional passion ownership local family activity ticket cinema development support manager museum continuous coaching feedback company provide roche business report peopletool resource support career development dialogue introduce degree feedback tool leader employee manager include online late launch globally start tool assessment identify area strength development help leader build understand key strength need overviews key experience require certain role development gap local career marketplace help employee con sidering change role learn career option learn development significant element employee development philosophy focus gain experience personal growth job total training investment believe employee build great skill capabilitie million chf work global innovative company expose training spend employee new challenge culture reason encourage chf employee pursue development opportunity total number training hour consist broad role challenge project temporary million international assignment average training hour employee work increase use stretch assignment number post graduate international move develop employee encourage student intern people particularly woman international assignment exclude chugai offer extensive relocation support help family settle spouse continue career succession management overall number international assignment risen maintain specific succession plan sharply recent year pri key position corporate operating group level marily result expansion emerge market monitor continuously ensure broad continue globalisation organisation percent deep talent pipeline special skill set broad age woman employee international assign experience require identify external ment increase pipeline talent addition onthejob development employee roche strength internal talent pipeline continue grow provide formal development opportunity mentor example key corporate executive committee coaching programme large roche affiliate site position fill internally broad organisation training curriculum available broad range position identify succession skill emerge market make significant invest planning continue strategic priority ment employee development organisation roche china academy cemai training center provide formal technical sale leadership train embrace diversity e employee region believe diverse inclusive workforce provide maintain special focus development future inspiration innovation business depend leader groupwide talent management include embrace diversity foster inclusive environment suite development programme leader enable differ view skill experience exchange stage career introduce programme freely openly executive catalyst focus lead change reinforce leadership commitment today employee woman worldwide global programme supplement divisional regional employee represent different nationality programme leadership development forum global headquarters basel participant test leadership skill simulate real different nationality life challenge intense threeday programme include senior leader observe assess participant strength point area improvement people roche business report diversity summit leader example pharmaceutical north america hold womens leadership summit launch gwise genen example roche diversity initiative include tech woman science engineering network diag roche diversity leadership summit nostic north america start woman leadership bring leader basel challenge perception network host healthcare businesswomen address role leader foster diverse inclusive association european leadership conference basel workplace day event include presentation headquarters conference feature panel diversity entrepreneurship woman leadership flexible executive numerous healthcare organisation fos work cultural diversity thinking style tere networking woman leader company topic attendee rate summit positively europe recommend colleague roche network site help foster diverse inclusive environment include basel open proud equal network launch encourage culture respect equality regardless sexual orientation basel family career network group employee family responsibility parent caregiver relative support well worklife balance south san francisco african americans biotechnology south san francisco stage strengthen tie generation additionally italy germany israel spain increase support employee introduce onsite child care holiday care child roche france establish gender diversity remain priority end charter diversity include childcare flexible work number woman key position go option equal opportunity commitment provide slightly compare previous year total num resource disabled charter include plan ber high potential identify indicate increase retain hire old employee consult work condi rigour highpotential process continue focus tion training skill development transition diversity expect continue make progress retirement roche turkey woman represent remain track achieve overall gender goal employee position roche turkey increase percentage woman key position prestigious prism award effort area international coaching federation leadership pipeline raise awareness group diver sity thing diversity inclusion grass root campaign encourage people lead number highpotential activity support diversity inclusion percentage woman highpotential gender diversity percentage woman global leadership programme woman total workforce woman line management support goal introduce initiative woman help woman career range basic executive position measure grant parental leave permit flex woman key position ible work schedule enhance mentor sponsorship programme maintain tie leadership network roche business report peoplereward recognition extend additional affiliate country employee competitive compensation benefit programme aspect roche strategy attract talented people moti vate retain current employee encourage strong fair employment practice performance company pay billion swiss franc remuneration employee treat employee fairly employment cycle include support affect organisa reward performance transparent consistent tional change example consolidation streamlin process encourages fairness continuous feedback dia ing research activity pre result reduction logue development continue position transfer position align remuneration policy process busi switzerland germany support impact employ ness unit establish common tool language ee ensure comprehensive package support employee performance appraisal help leader measure place include severance payment pro meaningful feedback encourage productive dialogue gramme outplacement service counselling access include use multirater tool employee onsite career lab retrain redeployment option result feedback request send september november activity include roche equal opportunity employer practice lab manager provide performance feed tolerate form workplace discrimination ensure roche compensation performance management principle apply effectively consi roche employment policy govern human right tently group labour relation roche site set inclusive workplace philosophy exact employment practice additionally add flexibility groupwide com chief compliance officer monitor implementation pensation portfolio empower manager use annual compliance policy association hr manager bonus longterm incentive acknowledge extraordi compliance officer roche site roche commit nary employee contribution te enforce policy site founda tion employment process design agree change longterm incentive programme monitor expect employee act accordance leader maintain competitiveness compensa policy tion plan address feedback strong alignment incentive share price performance revise plan update policy implementation january take effect underscore belief employee ownership enable employee earn equity combination stocksettle stock appreciation right respect employee right freedom association restrict stock unit collective bargaining currently approximately employ ees trade union member belong labour group additionally roche europe forum enable hr excellence represent interest employee country recognise strong employee performance enable align integrate process system finalise implementation common human web resource information solution chris serve foundation complete comprehensive service employee wwwrochecomemployee global career portal careersrochecom manage employee information key human resource pro employment policy wwwrochecomemploymentpolicypdf cesse group policy position guideline wwwrochecompositionspoliciesdownloadshtm commitment employee wwwrochecomcommitment chris available language roche legal entity health safety wwwrochecomenvironment employee operating country january compensation performance module chris people roche business report value innovation cobas hpv cintec test well screen cervical cancer cervical cancer develop slowly year screen programme base pap smear reduce number cervical cancer death country dramatically test foolproof woman miss pap test examine cell cervix abnormality disease cause persistent infection highrisk human papillomavirus hpv genotype hpv infection harmless important pinpoint infection likely cause cervical cancer roche cobas hpv test detect highrisk hpv identify woman great risk develop cervical disease cintec product help well identify precancerous lesion enable doctor remove unhealthy tissue cancer fully develop protect patient unnecessary treatment give woman peace mind safe receive appropriate care prevent cancer screen cervical cancer detect late symptom usually mean death sentence woman risk cervical cancer virus cancer cobas hpv test detect cintec plus test detect highrisk virus type protein associate genotype particularly cancerous cell transforma hpv tion p ki incidence screening year new case cervical cancer healthy hpv precancerous cervical tissue infection lesion invasive cancer succumb disease incidence high develop country lack screen programme develop region highrisk hpv type root cause case cervical cancer thousand woman die cancer infection hpv fairly common case body able clear virus woman infection resolve cervical cancer prevention programme persist lead cervical cancer relevant type predominantly base pap test hpv type consider high risk type hpv vaccination modern hpv screening slowly responsible approximately cervical cancer adopt forerunner italy cobas hpv test provide individual test result hpv introduce hpv primary screening pool result highrisk genotype enable instant region sweden intro identification woman high risk need immediate duce pilot programme stockholm intervention early test invent name physician george papanicolaou roche business report value innovation hpvenindd christine baze cervical cancer survivor patient advocate year old diagnose invasive cervical cancer despite fact go pap smear year day later radical hysterectomy week daily pelvic radiation round chemotherapy round internal radiation diagnose pap work screening get well accurate addition hpv test pretty amazing think doctor patient accurate information thing want woman know care body accurate screening possible screening base pap smear annual test miss woman precancer screen base molecular testing twostage approach identify woman precancer stage check cancer root cause hpv highrisk infection cobas hpv test stage check precancerous lesion web cintec plus test httpwwwrochecomvalueofinnovation hpvenindd employee participate roche children walk roche business report community involvement inaugurate second transnetphelophepa healthcare train bring primary healthcare remote region south africa support humanitarian social project aftermath hurricane sandy partner organisation philippine supply affordable solar power light people live shanty town tondo roche business report community involvement key figure breakdown give area humanitarian social project art culture science education community environment roche form year ago aim participate project collaborator contrib company direct human financial resource com ute expertise resource early possible munity project philanthropic initiative last stage share longterm risk commitment impact investment necessary achieve last benefit direct give area priority humanitarian responsibility philanthropic activity delegate social project science education art culture local affiliate operate coun community environment matter size project try select managing engagement locally cost focus outcome philanthropic activity well tailor activity local priority respond support engage generate tangible longterm quickly urgent need arise benefit people community measure innovation apply creative effective solution activity guide roche global donation societys challenge noncommercial sponsorship policy philanthropic donation sustainability deliver endure impact dynamic register accredited independent resourceconstraine world nongovernmental organisation multilateral organisation collaboration drawing strength skill notforprofit charity roche partner organisation individually tailor activity need project lighting philippine sunlight socalle solar bottle bulb powerful light small dark home plus environmentally friendly inexpensive easy roche philippine employee enter partner ship myshelter foundation philippine christian foundation reduce dependence electricity open flame light people live tondo shanty town liter light project use plastic soda bottle encase corrugate tin fill water bleach mount roof allow light pass home solar bulb hour install sunshine old plastic bottle fill year improve living environment water chlorine watt solar bulb refract family allow child read roche business report community involvementemployee involvement clinic rail phelophepa roche encourage employee involve describe local miracle train transnet community work live mean phelophepa healthcare train clinic rail bring engage personally enriching experience primary healthcare remote region south africa site site support employee community service doctor resident offer flexible work schedule broker volunteer assign ment coordinate group project refrain phelophepa mean good clean health launch exert influence type volunteer roche main external sponsor work employee engage transnetphelophepa funding primary healthcare community outreach ancillary service activity improve health world poor country offer secondment programme employee modest beginning threecar train service enable contribute skill assignment expand coach train humanitarian organisation develop country train run week year phelophepa deliver medi low low middle income economy cal service healthcare education reach programme allow employee participate people annually include patient month project dedicate improve health need care train staff visit school provide vital roche secondee contribute project india south africa health check medicine education child haiti employee unite common cause roche children walk walker roche site world participate oneday event raise money school orphan malawi employee roche site coun try participate humanitarian social project large philanthropic giving direct humanitarian social project believe improve human service support system effective way port european coalition positive people work help build strong healthy community malawi help child orphan hivaid day centre skill train nutrition educational assistance preference provide support yield outcome maintain longterm basis local level aftermath hurricane sandy strike north example country adequate healthcare east october genentech foundation infrastructure train healthcare worker hospital neighbour roche facility new jersey quickly provide general health awareness find investment edu major donation american red cross shelter recov cation prevention usually sustainable solution ery assistance emergency transportation meal medicine diagnostic donation foundation usbase private charitable foundation estab lishe genentech provide financial support spirit roche support project run qualified nonprofit charitable organisation community united nations childrens fund unicef malawi fund support health science education patient education ing helped build classroom pay school material advocacy like desk book literacy resource addition join unicef support primary school teacher training build new teacher training college southern malawi additionally roche provide financial sup community involvement roche business report illuminate dna roche sole corporate sponsor competition aim promote science study science career dna deoxyribonucleic acid essential broaden understand life science research organism normally find chandelier idea create chandelier model crystallise dna roche diagnostic germany help teacher intrigue dutch designer lucas maassen dna classroom experiment attractive vivid fragment crystallise roche molecular biology labora blue gene kit contain dna experiment precise tory magnify glass version crystal normally description lesson planning provide nominal fee visible microscope produce experimental kit complement theoretical instruction crystal manufacturer give teacher student handson opportunity learn basic technique molecular biology thousand glass orb later valerie crystal sister represent sister maassen assem roche ireland support primary school face bleed parent june vitra design terminate computer programme museum weil rhein germany art basel fund upgrade outdated computer lab work true collaboration lucas maassen roche scientist confrontation con school computer room officially reopen temporary dutch design exhibition museum donate computer roche ireland enable school provide student new skill include literacy numeracy word processing art culture roche actively cultivate support groundbreake con temporary art cultural project favour creative activi tie explore parallel innovation art science roche commission offer contemporary music artist challenge opportunity forge new frontier field start second year recognise contempo science education rary composer select recommendation artistic director lucerne festival partner roche business found excellence innovation sci commission commission work premiere ence help develop future scientist public lucerne festival summer composer standing life sciences support programme conductor matthia pintscher grant sixth roche enhance science education draw talent science career commission award composition chute dtoile engage outstanding young scientist teacher support creative expression monthly roche switzerland roche active supporter swiss youth n jazz event rochefounde museum science foundation raise awareness appreciation tinguely bird eye jazz club bring inventive science child young people support jazz community basel roche continent foundation national competition study week student science music fine art swiss talent forum think tank young adult europe select spend week salzburg austria activity salzburg festival attend workshop explore common ground creativity art science simply science website design generate interest young people life science host swiss foun dation website pilot innovative national secondary school class competition science roche business report community involvementgene sequence zoo kumari asian elephant calf smithsonian national zoo live month die persistent internal bleeding search cause bleed pathologist zoo discover aggressive herpe virus specific elephant elephant endotheliotropic herpe virus eehv zoo launch study eehv animal disease powerful gene sequence device donate roche gs junior system instal smithsonian conservation biology institute system support research cause high mortality rate elephant live captivity grow number eehv case wild scientist believe disease connect loss animal natural habitat community environment latvia high infant mortality rate low birth rate europe roche latvia collabora organisation individual commit tion neonatology obstetric expert initiate save resource support local community protect newborn aim reduce infant mortality rate half natural resource genentech give week base situational datum assessment series recom opportunity employee roche affiliate mendation range improve medical infor support community employee help mation quality improve usage ultrasound exami donation form cash good employee time nations ministry health adapt new policy nonprofit organisation participate volunteer implement propose recommendation project donate air mile barrel educational supply clothing food information find wwwrochecom example community involvement indicator measure success humanitarian science art culture community social project education environment roche logistic consultation scientist workshop roche expert workshop workforce volunteer employee volunteer disable trainer leader local programme engagement employee walker raise sciencetechnology hour collaboration team build event fund vulnerable educational material service agency child volunteer tutor secondee day mentor community individual screen teacher professional museum visitor individualsfamilie beneficiary student teacher train development workshop art science student assist community child enrol child aid tutor joint project service secondary school secondary student child creativity family counselling disabled child assist conduct research workshop session concert audience home renovate infrastructure social service centre placement student creativity workshop cultural group sustain system renovate teaching method establish recreation programme change prototype school adopt performance establish construct visitshit online commission music public site clean mobile health clinic oper resource ongoing museum ation construction training course graduate operation community involvement roche business report value innovation mining biotech roche penzberg innovation create value local economy roche penzberg biotech hub locate site coal outskirt bavarian town penzberg germany roche buy site invest billion euro stateoftheart facility create additional job employee hold university degree impact local economy innovationdriven company like roche penzberg enormous create far aboveaverage wealth community people employ roche penzberg extremely qualified high salary level bring increase tax receipt consumer spending order product roche need highqualifie labour supply good service result innovation trigger substantial multipli effect local economy germany increase employment employee company co sn ump ti company coth pr ny salary nv e st ei n cs lu p pl not billion euro invest big payer business tax penzberg region u p distinct external network academic ply biotech company complete biotech value chain tax science patient social security company horst seehofer prime minister bavaria penzberg prime example bavarias state successful modernisation drive roche strong society commitment difference benefit country small mining town rural upper bavaria internationally network location research innovation generate sizeable number highly qualified job web httpwwwrochecomvalueofinnovation roche business report value innovation penzbergenindd impact penzberg germany production value euro spend roche penzberg generate additional euros germany employment job roche penzberg generate additional job germany state society roche tax penzberg social security state society nv e st ei n cs lu p pl salary company not co sn ump ti sec ur ito yct iaa lx n roche direct impact employee pply u salary indirect impact company employee indirect impact company penzbergenindd percent reduction greenhouse gas emission roche business report safety security health environment increase energy efficiency employee reduce ecological impact employee decrease water consumption roche business report safety security health environment key figure roche accident rate rar track reach goal energy efficiency gjemployee track reach goal co efficiency temployee track reach goal total environmental impact million impact pointsemployee track reach goal roche refer safety security health environman inclusion report base analysis iden tal protection approach sense tifie follow priority topic responsibility methodically issue occupational accident occupational illness concern quality productivity costefficiency energy consumption use sustainable energy total ecobalance ecological impact operation strive continuous improvement pos total toxicity waste water sible economically viable seek sustainable longterm closing gap identify internal audits improvement organisation change behav compliance law regulation iour adapt equipment recent standard improvement performance supplier develop innovative process service provider reduction total risk load education employee relevance materiality maximise value reporting strive provide improve monitoring information balance relevant stakeholder performance identify follow topic believe material business sufficiently important report employee engagement training people respect health integrity wellbeing prevention key effective management environment conservation resource employee safety health environmental material asset functional efficiency protection team roche site identify risk business continuity cost develop mitigation plan communicate policy guide compliance external internal regulation line employee stakeholder regard look believe education awareness train good material issue consider potential future develop way foster employee engagement responsibility ment analyse need feasibility act define perfor mind conduct regular training session mance indicator set goal target regional conference workshop provide online tool local language employee employee materiality influence external internal factor participate hour train instance external regulation law affect strategy report convention industry stakeholder regularly review effectiveness management expectation internally organisation policy strategy system encourage employee identify area improve goal determine materiality issue con ment database good practice employee sidere factor identify area frequently share knowledge exchange new idea pro roche business report safety security health environmentcedure proposal database ecompetition adopt area organisation start roche ecompetition give employee annual roche responsible care award recognise opportunity contribute idea suggestion good contributor application good practice improve sustainability culture performance employee receive entry award raise awareness environmental protection encour announce winner quarter age sustainability identify cost saving environ mental protection activity audits assessment assess performance compare result ecompetition submission result significant law regulation internal standard set improvement variety area include energy conserva organisations international chamber com tion waste reduction decrease consumption water merce business charter sustainable development inter raw material reduce air pollution additionally num national organisation standardisation chemical ber submission address social aspect sus industrys responsible care programme tainability suggestion improve certain manufacturing process result major cost saving conduct internal audits year chemical idea include measure reduce energy consumption pharmaceutical diagnostic manufacturing site airconditione system prove useful multiple site critical operation stipulate necessary improve ment audit audit frequency facility sixth edition ecompetition winner determine risk potential strategic importance past select entry reduce energy consump formance sitespecific circumstance plant man tion get interest improve logistic agement local officer conduct frequent spot respect packaging transportation concept check inspection assess compliance stan interesting idea reference use heatdriven dard sterle engine cool purpose expect contract manufacturer supplier service pro vider meet standard ensure compliance standard thirdparty auditor see light turning retain periodically inspect operation sup plier issue recommendation improvement genentech south san francisco goal reduce event unsatisfactory performance terminate energy use build campus contract refuse award new contract supplier year help achieve member green gene nearly member employee club support green practice audits elect find way eliminate reduce unnecessary lighting internal audits spark idea member green genes followup energy team club form army darkness time volunteer audit building work document external audits ing lighting control condition operate hour followup campus building equip time occupancy sensor automatically turn light audit find ineffective lighting control area light direct material supplier switch light issue resolve quickly easily sche internal followup audits site improve uled lighting system upgrade army darkness performance recommend improvement follow effort contribute lighting project save esti ing audits include increase involvement line mate million kilowatt hour year management improve risk analysis safety security health environment roche business report detail find chapter manufacture increase sale expenditure environmental protec procurement tion limited environmental harm reduce high eer value ecoefficiency minimise environmental seek improve eer reduce material energy footprint consumption waste renewable resource effort result eer improve commitment sustainable development proactively seek employ new sustainable technolo gy process minimise impact environ ecoefficiency rate eer ment establish groupwide goal ecobalance sale management roche site establish strategy million chf objective reduce environmental impact environmental well suited local circumstance expenditure million chf total environmental impact employee environmental million impact point improvement impact target improve ecobalance level environmental impact point eer x ecoefficiency ecoefficiency aim minimise ecological damage maximise efficiency firm production process addition expend million swiss franc envi achieve energy material water ronmental purpose expense safety security decrease elimination hazardous emission byprod amount million swiss franc total uct increase recycling quantify ecoefficiency expense measure approximately ecoefficiency rate eer ratio sale expenditure million swiss franc compare million swiss environmental protection environmental impact point franc decrease approximately accordance swiss federal office envi ronment foen efficiently business activity increase energy efficiency goal reduce total energy consumption fossil fuel electricity gigajoule gj employee level level ecobalance impact point longterm goal reduce energy consumption employee approximately baseline level roche ecobalance refer consumption energy resource pollution cause business plan increase proportion sustainable energy activity describe total environmental impact use total energy consume strategy operation achieve objective improve energy efficiency aggressively substitute fossil fuel sustainable allocate environmental impact point weight fac energy tor ecologically relevant parameter consumption resource raw material water energy energy conservation priority group waste emission air water soil obtain main source greenhouse gas emission view demand place earth ecosystem co second reduce energy con point add relate total number sumption lower operating cost systematic approach employee enable monitor environman energy management include tal impact employee million impact point construct energyefficient building retrofit heating cool air conditioning installation roche business report safety security health environmentecobalance number impact point box raw material primary energy emission air water emission water landfille waste environmental impact employee million impact point roche product adjust range acceptable temperature office country fuel reduction result saving approx workplace million swiss franc purchasing energyefficient equipment include hybrid increase use sustainable energy bring total dieselefficient car sustainable energy consumption change work process review employee travel need improvement result overall decline energy consumption slight increase continue focus responsible use number employee energy consumption gj resource continuous reduction energy consumption employee surpass target gj activity result improved energy usage area project team roche indianapoli improve organisational reduction energy use building stationary efficiency reduce international air travel leader equipment gas fuel oil waste electricity business unit facetoface meeting decrease car fuel consumption central celle person day productivity gain include eastern european middle eastern african indian avoid travel day international domestic safety security health environment roche business report ecobalanceenindd flight avoid result save approximately giga energy use type joule energy approximately tonne co emission swiss franc overall area natural gas business travel reduction effort successful energy consumption air travel increase grid electricity lower greenhouse gas emission district heating greenhouse gas ghg emission roche originate generation use energy goal improve energy air travel efficiency reduce energy consumption apply ghg emission reduction measure waste tonne employee level reduction level expect achieve oil reduction substitute fossil fuel energy sustainable source car fleet actively seek decrease ghg emission establish internal energy standard ensure new plant building greenhouse gas emission co equivalent design maximum energy efficiency optimise retrofit exist asset total emission reduce fuel use heat cool million tonne operate site able reduce ghg emis total emission sion result energy save measure million chf sale tonne energy use terajoule baseline total energy use total energy use million chf introduce new technology sale total energy use fuel cell technology choose good option employee refurbish energy supply roche molecular diagnostic pleasanton california project engi neere team receive innovation award reduce halogenate hydrocarbon emission senior management roche molecular diagnostic halogenate hydrocarbon refrigerant cool equipment chlorinate compound deplete fuel cell produce electricity heat hydrogen ozone layer fluorinated partially fluorinate electrochemical reaction combustion similar considerable global warming potential battery optimum overall efficiency heat exchanger persistent stay atmosphere long recover heat heat building period time example chlorodifluoromethane commonly pleasanton site process produce usable propellant refrigerant remain atmo electricity heat commonly know cogeneration sphere approximately year cogen combine heat power chp depend heat site typical efficiency plan reduce halogenated refrigerant rate fuel cell range roche site site acquire recent year electricitytoheat ratio approximately genentech ventana work sepa rate timeline roche business report safety security health environmentsince significant progress reduce emission air tonne emission halogenate hydrocarbon eliminate halon reduce fully halogenate compound exclude genentech site ventana vocs particulate recent acquisition lack alternative coun nitrogen oxide try complete elimination chemical sulphur dioxide unrealistic continue examine alternative work refrigeration supplier reduc tion manage waste waste parameter ecobalance waste reduction halogenate hydrocarbon tonne target reflect goal improve group ecobalance maintain waste reduction goal individual site set inventory groupwide goal primarily large yeartoyear fluc emission tuation waste construction demolition activity roche pharmaceutical diagnostic company minimise air emission produce relatively low volume chemical gener minimise emission air variety technology ate small quantity chemical waste con practice priority avoid pollutant reduce tinue reduce low volume waste pro duction quantity pollutant control remain pollutant emis biotech product increase chemicalbase product sion line ecobalance goal overall objective decline genentech hillsboro site oregon usa emission low level achieve example divert solid waste recent year landfill earn recycle work award local government emission strategy prescribe continuous improvement programme manufacturing site include flue gas production pharmaceutical diagnostic product rise scrubber reduce nitrogen oxides sulphur diox overall chemical waste x ide incineration freeze process general waste increase reduce release volatile organic compound voc reduce energy use accept responsibility waste generate opera tion include previously deposit site land basel site commission installation fill permit landfilling resort freeze vocs waste air discharge manufacture inert material slag incineration ash building equipment process use liquid nitrogen depend availability suitable local wastetreatment replace energy intensive process incinerate waste plant dispose nonhazardous general waste air similar installation complete chemical authorise landfill manufacture plant florence usa end switzerland roche company continue clean emission air low level fluctuate hazardous waste landfill klliken bonfol year year result significant variability mer user kesslergrube landfill grenzach germany instance group emission increase roche study possible remediation option x tonne prolong use emergency generator evaluate remedial option site belle single site ville new jersey usa june roche announce plan shutdown operation approximately acre site nutley new jersey consequence view future sale property roche accelerate exist effort state regulatory oversight fully investigate remediate safety security health environment roche business report soil groundwater condition site early remedia record organic emission water total organic car tion activity complete underway include bon toc process wastewater treatment plant groundwater treatment soil excavation operation soil discharge wastewater pollutant comply vapour extraction system fully relevant regulation include pretreatment require ment elimination rate wastewater potential responsible party roche involve treatment plant high seek minimise investigation remediation project different environ contamination water mental site reduce discharge toxic poorly biodegradable sub stance heavy metal waste tonne reduce generation wastewater treat pretreate wastewater ozone case non poorly degradable contaminant general waste produce result continuous effort reuse reject water general waste reverse osmosis cool tower boiler improve million chf cool process water consumption decrease sale million cubic metre penzberg site ger chemical waste instance selfpowere highefficiency wastewater produce treatment plant earn award innovation envi chemical waste ronmental responsibility local programme iden million chf tified opportunity reduce water consumption sale genentech south san francisco site evaluation identify improvement reverse osmosis portion water puri fication plant save estimate million gallon conserve protect water resource approximately swiss franc year furthermore roche support global effort promote water protection pilot study launch treat reuse wastewater conserve water reserve improve access clean drinking neutralisation cascade successful save water longterm goal reduce total wastewater toxicity additional million gallon approximately baseline meantime con swiss franc year tinue investigate reliable performance indicator mea surement method establish baseline strive water usage discharge stabilise water consumption group half water draw cool circuit water withdraw water chemically contaminate discharge million cubic metre analysis rest purify treatment plant water release waterway million cubic metre wastewater discharge operate site consume large treatment plant volume water area water scarcity adopt million cubic metre conservation reduction programme accord local organic matter condition need example californian site use discharged drought resistant landscaping site reduce water watercourse consumption treatment tonne collect recycle water cool tower create heavy metal closedloop system discharge reuse cleaning water rinse recycling watercourse water treatment kilogramme reduce cool requirement improve cool pro cesse improve heat recovery roche business report safety security health environmentin transfer million cubic metre water water management local issue roche treatment plant result discharge tonne purposely decide set global target surround water organic matter addition discharge kilogramme management encourage local target locally heavy metal leach metal pipe water management closely effectively operation watercourse monitor heavy metal emission roche site low level new process activity significant support biodiversity effect amount emit example cleaning galva nised equipment dismantle mannheim roche support principle resource stewardship define site germany result increase zinc washout convention biological diversity cbd main objective cover conservation biological diver toc emission reduce substantially roche sity sustainable use component fair equitable rio de janeiro plant modifying process new clean sharing benefit use genetic resource e agent different production programme avoid use noncommodity natural resource material water management source product discovery development water consider basis life equally important pharmaceutical discover develop com industrial activity production pharmaceuti mercial product derive natural plant microbial animal cal diagnostic possible sufficient amount genetic material use resource guide clean water availability highquality water critical principle goal cbd business process chemical biotech pharmaceutical diagnostic manufacturing involve water operate facility area pro reagent solvent clean agent globally poor quality tecte high biodiversity value roche site require water result high cost purification risk access city infrastructure locate urban product contamination pharmaceutical industry addi environment tion water energy carrier refrigeration heating installation safeguard employee appropriate water management roche property operation roche group site work pro gramme reduce water consumption recycle reuse health safety water context complete assessment employee health safety priority primary exposure roche business water risk objective roche accident rate rar year focus availability water suffi reduce reduce cient amount acceptable quality roche illness rate rir rar cor respond number work day lose occupa evaluation water tool world business tional accident employee year roche site rir council sustainable development identify site correspond number work day lose occu eventually face water scarcity near future tool pational illness employee year use statistical information body food agriculture organization un world resources insti maintain integrate programme employee consulta tute university new tion workplace inspection train business area approach promote strong safety culture second evaluation concentrate future development empower employee report address safety site surround area water competitor issue expect similarly rigorous policy con negatively influence future growth finally site tractor encourage safety wellbeing identify need indepth water analysis employee sell discount protective equipment respect development improvement water recreational activity conduct bicycle safety check supply activity roche legans madrid spain optician work site adjust lense sell safety security health environment roche business report glass day roche pleasanton usa volunteer tion regard significant business risk roche small ergonomic team know locally ergo angel perform specialist team comprise member global competi dropin ergonomic evaluation employee tive intelligence security legal datum compliance group security brief employee roche diagnostic rotkreuz ongoing effort improve workplace roche basel topic campaign contin safety result decline approximately ued remain r site extend number workrelate accident million work hour operational area need employee report occupational accident increase frequency compare security activity include conduct result number lose day increase western europe security workshop mannheim germany overall roche accident rate site security officer chief security go officer discuss priority issue product counter feite information security number report case occupational ill ness increase case number work day lose decline pharmaceutical environment result roche illness rate decrease consider entire lifecycle drug take step minimise release pharmaceutical environment occupational accident illness profile remain consis stage tent slip fall repetitive strain represent majority workrelate incident trace pharmaceutical product enter environment report workrelate fatality employee fall variety way include manufacturing process cycle build campus tragi improper disposal unused medicine natural cally die day accident process follow normal patient use patient use generally recognise primary contributor employee safety health evidence suggest exposure trace concen basis tration surface ground drinking water pose roche accident rate harm human health risk aquatic life think roche illness rate great scientific study identify short number term effect exposure lowlevel concentration workrelate pharmaceutical research conduct accident evaluate potential longterm impact recognise case need research possible effect support workrelate scientific work field illness workrelate design manufacturing site reduce risk active fatality ingredient enter wastewater support pharmaceu workrelate tical takeback programme employ proactive measure accident prevent release product environment million work offer financial incentive ensure unused hour date product return retailer supply chain establish policy require return waste pharma security ceutical product incinerate dispose goal protect employee visitor physical landfill asset intellectual property product harm loss support research effect pharmaceutical roche start information security awareness environment campaign address priority employee work provide environmental risk assessment authority r departments theft loss business critical informa new medicine roche business report safety security health environmentlegislation compliance environmental protection meet local law regulation policy basis target date rigorous external standard improve energy efficiency gjemployee fully track registration chemical material accord european legislation registra increase share sustainable tion evaluation authorisation restriction chemical energy total energy consumption reach requirement globally harmonise system classification labelling chemical reduce co emission employee line improve energy consecutive year prior incur sig efficiency nificant fine sherelate violation reduce total environmental impact assess small fine minor infraction calculate ecobalance accord respect worker accident result lost day swiss federal office breach management regulation relate environment bafu employee specific risk assessment particular process reduce total waste water toxicity goal education web basis target date environmental protection wwwrochecomenvironment improve education increase eer ecobalance wwwrochecom training employee factsheetecoefficiencypdf goal wwwrochecomshegoal average hour year performance wwwrochecomsheperformance service wwwrochecomsheservice policy guideline position paper wwwrochecomresponsibility environmentshemanagementpolicyguidelinesandauditshtm safety basis target date improve roche accident rate rar rar reduce number occupational accident cause lose working day case work hour roche illness rate bring number case occupational illness cause lose working day case work hour safety security health environment roche business report value innovation n eric e g revenue research develop cycle drug ment development e ar ti r k e e patent protection year rocephin s model list essential medicine clude active ingredient develop roche rocephin cefriaxone highly effective treatment bacterial infection include purulent meningitis approval rocephin quickly roche topselle drug world number injectable antibiotic generic pro duction ceftriaxone naturally attractive proposition patent expire time ceftriaxone generic market produce different country web httpwwwrochecomvalueofinnovation roche business report value innovation patentprotectionenindd innovation pharmaceutical industry last contribution world health discovery development new drug high risk development cost billion swiss franc year complete drug candidate average receive regulatory approval patent drug copy easily quickly composition declare innovation continue drive medical breakthrough investment research deve lopment compensate new drug adequately protect patent come patent temporarily confer exclusive right market product protect ensure innovation reward search new treatment continue offpatent product replace generic avail g e n eric ida er yng ete ait f r sa cn ad ti ole nad able society low cost perpetuity l e es ato opti d ar n p r te cycle drug research develop ment e rse tin g c lin ic l development e ar investment clinic l yu ed ai ss prof patrick aebischer prsident cole poly technique fdrale de lausanne patents essential research life science protect knowledge raw material provide incentive highrisk investment patentprotectionenindd foundation year ago roche year specialise leader researchfocuse healthcare combine strength pharmaceutical diagnostic roche business report corporate governance roche commit serve stakeholder basis successful implementation commitment stakeholder corporate governance principle accordingly focus business activity sustainable value creation innovation prescribe management culture conforming recognise standard corporate governance policy transparent communication remuneration report roche success depend ability dedication people recognition form basis performanceoriente remuneration policy system roche business report corporate governance corporate governance roche commit serve stakeholder basis curriculum vitae member board director successful implementation commitment cor corporate executive committee publish porate governance principle accordingly focus website business activity sustainable value creation innova tion prescribe management culture conforming rec detail refer follow report ognise standard corporate governance policy transparent communication board director strong board director represent interest shareholder stakeholder highly skilled th annual general meeting agm roche hold manager act integrity extremely important ltd march shareholder reelect john bell andr hoffmann franz b humer members board dow jones sustainability index designate director term year provide arti roche supersector leader healthcare fourth con cles incorporation secutive year sustainability core business practice award reflect commitment run organising meeting immediately follow agm business way ethical responsible create board director determine structure compo longterm value stakeholder sition committee show corporate governance report set structure agm march board director nom process rule roche take basis inate andreas oeri pius baschera paul bulcke william function corporate governance roche com burns christoph franz deanne julius arthur levinson ply relevant corporate governance requirement peter r voser beatrice weder di mauro reelection particular applicable law swiss stock exchange board term year provide article swiss exchange directive include commentary incorporation thereto swiss code good practice corporate governance promulgate swiss business federation bruno gehrig vicechairman board director economiesuisse company internal governance frame lodewijk jr de vink longterm member board work particularly article incorporation bylaw director decide retire member board embody principle need ensure com director board director thank member pany business manage supervise manner long valuable contribution successful continu consistent good corporate governance include ing development roche necessary check balance agm march board director addi print annual report contain select link tionally nominate severin schwan election board roche website wwwrochecom reader provide term year provide article incorpo snapshot company report date ration direct source consult time uptodate information corporate governance roche annual report cover single finan cial year end december website contain informa tion permanent nature late roche news company articles incorporation bylaw httpwwwrochecomaboutrochecorporategovernancehtm roche business report corporate governancecorporate executive committee information relate corporate governance sophie kornowskibonnet general manager roche pharma france appoint head roche group structure shareholder nere group headquarters basel join roche operate business organise divi enlarge corporate executive committee new member sion pharmaceutical diagnostic pharmaceuti february report severin schwan ceo cal division comprise business segment roche roche group succeed dan zabrowski take pharmaceutical chugai genentech head roche apply science diagnostic division segment integrate roche phar locate penzberg germany february dan maceutical diagnostic division consist fol zabrowski member diagnostic leadership team low business area apply science diabetes care report roland diggelmann coo division molecular diagnostic professional diagnostic tis roche diagnostic september sue diagnostic business activity carry group subsidiary associate company detailed jeanjacque garaud head roche pharma research information roche holding ltd significant sub early development pred member enlarge cor sidiarie associate company include company porate executive committee retire roche june list information domicile share capital equity effective july mike burgess discovery interest list finance report note translational area dta head oncology head roche group consolidated financial statement subsidi large molecule research assume adinterim position arie associate head roche pharma research early development major shareholder list finance report note pred sit enlarge corporate executive com roche group consolidated financial state mittee john c reed appoint head roche ment equity attributable roche shareholders pharma research early development pre mem relate party page note ber enlarge corporate executive committee succeed financial statement roche holding ltd significant ing mike burgess report severin schwan effective shareholder april andr hoffmann vicechairman board director andreas oeri member board director effective september daniel oday appoint coo chairman board corporate governance sus division roche pharmaceutical succeed pascal soriot tainability committee serve respective capacity follow resignation time roland diggel board committee representative mann head asiapacific region roche diagnos shareholder group pool voting right receive tic succeed daniel oday coo division roche diag remuneration set forth remuneration report nostic finance report note roche group consolidate financial statement relate par information member board director includ tie note financial statement ing year elect year roche holding ltd board executive remuneration term end member corporate relationship exist sharehold executive committee list page ers pool voting right board director corporate executive committee crossshareholding capital structure information roche capital structure provide finance report note financial statement roche holding ltd additional detail contain article incorporation roche holding ltd httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm corporate governance roche business report change equity detailed finance report note annual general meeting elect member financial statement roche holding ltd board director stagger election nominee vote separately article company share capital swiss incorporation roche holding ltd minute franc divide fully pay bearer share th annual general meeting roche holding ltd hold nominal value swiss franc march restriction exercise vote right exception franz b humer william burn share deposit share vote arthur levinson member board restriction director member roche corporate execu authorise conditional capital tive committee serve executive capacity addition nonvoting equity security nes group subsidiary financial year precede issue bearer form form current reporting period share capital confer voting right ne con internal organisation board director fer right share participate available division authority responsibility board earning liquidation proceed follow repay management remit board committee ment share capital roche ne right information control mechanism available taine thereto include provision protect board dealing corporate management gov interest nes holder describe article erne bylaw incorporation roche holding ltd board director roche holding ltd organise information debt instrument issue ensure group conduct business respon outstanding bond provide finance report sibly focus longterm value creation note roche group consolidated financial state end roche board delegate certain responsibility ment debt committee composition chairperson additional information employee stock option pro january describe com vide finance report note roche group mittee authority responsibility define detail consolidate financial statement employee stock option bylaw board director equity compensation plan include detailed committee presidium chair information roche option plan roche independent director restrict stock unit plan ff accord bylaw board director board roche issue option apart employee stock meeting convene chairman present option stocksettle stock appreciation right ssar request member roche board meet option issue connection debt instrument year assess chairman performance option award employee debt meeting attend chairman chair instrument issue effect vicechairman roche share capital management information system board director inform important issue board director corporate executive committee sale performance etc monthly basis board information member board director access electronic information platform provide include year elect timely information board director board year term end member committee system control set forth corporate executive committee list page curricula vitae current member year body information include information board membership available con tinuously update internet httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm httpwwwrochecomaboutrochecorporategovernance annualgeneralmeetingshtm httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm httpwwwrochecomaboutrochecorporategovernance httpwwwrochecomaboutrochemanagement committeeshtm boardofdirectorshtm httpwwwrochecomaboutroche httpwwwrochecomaboutrochecorporategovernance managementexecutivecommitteehtm articleofincorporationhtm roche business report corporate governance board director establish system control conduct operational audits group audit deter continuously monitor audit committee mine management response risk surround corporate governance sustainability com business process system evaluate mittee consist follow element appropriateness completeness efficiency pro report operate financial risk risk management cesse control action plan implement nece system sary change enhancement develop r oche system place identify manage businessauditee track completion type risk potentially affect business roche statutory auditor risk management charter set approach chief compliance officer compliance officer accompany responsibility pharmaceutical subsidiary diagnostic division global function conduct safety health environmental protection depart mal risk assessment process year ment develop risk plan material risk corporate sustainability committee monitor deviation review regular science ethic advisory group seag issue performance dialogue consolidate group risk relate genetics genetic engineering establish report include target risk profile discuss corporate executive committee approve member corporate executive committee group business plan present invite attend meeting board director audit committee process subject regular report person agenda item concern review finding present audit committee situation warrant member enlarge cor board porate executive committee invite attend f detail risk management include risk factor board committee invite chairman board risk management charter risk management corporate executive committee member deliver report compliance website financial risk management committee meeting elect commission inde specifically describe finance report pendent expert report service consul system internal control financial reporting tant page finance report internal audit g roup audit report general counsel direct access give regular briefing audit commit tee ongoing activity audit report chief audit risk advisory executive attend audit com mittee meeting external auditor g roup audit independent appraisal function evaluate review group activity service management annual audit plan yearly define focus area eg emerge market thirdparty manage ment validate senior management present audit committee roche group commit maintain high standard internal control worldwide operation management responsible assess business risk aspect oper ation implement effective efficient pro cesse control whilst ensure compliance internal external rule regulation httpwwwrochecomcorporateresponsibilitybusinessethic riskmanagementandcompliancehtm httpwwwrochecomcorporateresponsibilityenvironmenthtm additional information provide finance report note httpwwwrochecomcorporateresponsibilityhtm roche group consolidate financial statement risk management httpwwwrochecomcorporateresponsibility csrresearchanddevelopmentgeneticsandbioethicshtm corporate governance roche business report board board committee attendance corporate governance presidium nomination remuneration audit sustainability board committee committee committee committee number meeting f b humer b gehrig hoffmann p baschera j bell p bulcke w burns l j r de vink ch franz julius levinson oeri p r voser b weder di mauro member committee franz b humer invite guest board committee meeting year blackout period impose corporate governance sustainability committee senior employee prohibit trading com meeting approx hour pany stock follow blackout period effect composition board committee remain december january unchanged march april april board director regularly conduct assessment june july performance october october members corporate executive committee blackout period change chairman maximum ordinary notice period month board director circumstance warrant management contract fall board director meet meeting generally scope subsection annex directive hour length addition information relate corporate governance day meeting threeday visit major sub sidiary board committee meet follow remuneration shareholding loan presidium board directorsnomination commit detail remuneration shareholding loan tee meeting approx hour set forth separate remuneration report page remuneration committee meeting approx finance report note hour roche group consolidate financial statement equity audit committee meeting approx hour attributable roche shareholder relate party page list note financial statement roche holding ltd board executive remuneration board executive share holding page figure indicate actual length meeting include director extensive premeete preparation postmeete followup activity remuneration committee member permit contribute attend remuneration committee meeting matters concerning deliberate decide roche business report corporate governance participatory right shareholder report statutory auditor consolidated finan participatory right shareholder define cial statement financial statement roche article incorporation roche share find page respectively year issue bearer restriction admission finance report annual general meeting exception share deposit specify period date kpmg receive follow remuneration service meeting admittance card issue statutory auditor roche holding ltd audi shareholders provide article tor roche company include chugai incorporation shareholder elect represent party annual general meeting article incorporation contain restriction exercise vote million chf right quorum requirement stipu auditing service late conformity swiss code obligation auditrelated service article incorporation shareholder accounting service represent share nominal value million assurance service swiss franc request placement item tax consultancy service agenda annual general meeting total later day date meet statutory auditor elect year annual change control defensive measure general meeting article incorporation contain provision mandatory bid rule swiss law apply information policy changeofcontrol clause component provide article incorporation corpo remuneration base roche ne terminate rate notice publish swiss official gazette event acquisition vest period restriction commerce daily newspaper designate preexisting award remove board director basler zeitung finanz und wirtschaft option exercise immediately lagefi le temps neue zrcher zeitung roche report halfyear fullyear result business relationship statutory auditor report publish print online format medium annual general meeting roche holding ltd event addition detail thirdquarter sale fig march shareholder vote appoint kpmg ag ure publish year april october kpmg statutory auditor base exist legal current list publication date available english requirement swiss code obligation article german internet concern maximum term office seven year relevant information document include medium auditor charge ian starkey replace predecessor john release investor update presentation analyst morris auditorincharge start business year investor conference available internet fur information long auditor auditorin ther publication order email fax telephone charge serve capacity provide baselwebmasterrochecom statutory auditor participate audit commit tel tee meeting prepare write oral report fax result audits audit committee oversee contact address investor relation f hoffmann assess auditor make recommendation la roche ltd investor relation group finance basel board information authority responsibilitie switzerland audit committee article bylaw tel statutory auditor participate meeting audit fax committee httpwwwrochecomaboutrochecorporategovernance httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm articleofincorporationhtm httpwwwrochecomaboutrochecorporategovernance httpwwwrochecommediahtm articleofincorporationhtm httpwwwrochecominvestorshtm corporate governance roche business report additional information include detail specific contact person available internet chief compliance officer compliance officer network chief compliance officer compliance officer network commit ensure roche group code conduct consistently comply roche group serve contact person shareholder employee customer supplier general public issue relate implementation compliance code employee par tie aware violation roche group code conduct bring attention manager supervisor report chief com pliance officer ur jaisli direct phone number email ursjaislirochecom disclosure treat confidentially addition end employee anonymously report irregularity complaint mother tongue speakup hotline addition roche establish business ethic inci dent report beir system enable chief compliance officer capture track monitor allege violation initial report local compliance offi cer resolution business ethic incident record system local compliance officer receive specific concrete information material allege violation roche group code conduct certain predefine category corporate governance sustainability committee audit committee board director inform sub stantial violation chief compliance officer report general coun sel submit regular report corporate gov ernance sustainability committee audit committee board director nonapplicabilitynegative disclosure expressly note information contain mention nonapplicable omission construe negative declaration provide swiss exchange corporate governance directive commentary thereto httpwwwrochecominvestorscontactshtm httpwwwrochecomaboutrochecorporategovernance codeofconducthtm httpwwwrochecomcorporateresponsibilitybusinessethic riskmanagementandcompliancehtm roche business report corporate governance corporate governance roche business report remuneration report remuneration report principle summary main activity roche success depend ability dedication outlook people recognition form basis perfor follow key development decision manceoriente remuneration policy system remuneration committee assist consultancy roche strive create innovative medicine diag tower watson regularly track base pay roche nostic product benefit patient require outstand director market datum director pay lead ing performance employee take continuous ing global pharmaceutical company major innovation help patient sustain revenue create long swiss company base remuneration roche direc term value innovation enable pay competitive compen tor remain unchanged year sation employee distribute rise dividend base salary fix pay corporate executive com stockholder dividend increase th mittee cec member remain unchanged year row primary aim remuneration case daniel oday daniel odays base salary policy encourage longterm focus align man increase follow promotion coo division roche agement interest interest roche shareholder pharmaceutical holder roche nonvoting equity security nes bonus variable pay cec member con sist entirely cash payment case severin year remuneration committee roche board schwan reflect sale growth strong growth director meets twice set remuneration earning share nonvoting equity security board member member group corporate development rich develop pipeline executive committee base pay bonus stocksettle stock stocksettle stock appreciation right ssar variable appreciation right ssar policy decision pension ssar grant cec member vest benefit term performance share plan psp award year exercise seven determine annually board director act year grant date unexercised ssar lapse recommendation remuneration committee compensation fair value ssar calculate grant date trinomial model remuneration committee track market datum salary american option detail lead global pharmaceutical company ssar grant strike price report finding board external consulting ne price december time firm tower watson assist roche perform market com value recipient change roche parison information remuneration committee remit ne price improve power procedure make remuneration decision performance share plan psp award variable find bylaw roche board director case psp psp psp outline section principle cycle payout award target ne govern specific remuneration component psp cycle plan key performance meet ric total shareholder return tsr calculate month move average constant chf exchange rate remuneration committee decide chief executive officer ceo cec member acquire roche share andor nes equivalent annual base salary ceo annual base salary cec peer set abbott laboratories amgen astella astrazeneca bayer becton dickinson bristolmyers squibb eli lilly glaxosmith kline johnson johnson merck co novartis pfizer sanofiaventis takeda httpwwwrochecomaboutrochecorporategovernance abb credit suisse holcim nestl swiss ubs zurich insurance articleofincorporationhtm group actelion nobel biocare sonova straumann synthe roche business report remuneration reportmember respectively end retain key principle underpin policy holding long serve cec focus value creation addition applicable statutory provision roche long pay performance term incentive plan include option partially reclaim enable employee share company success distribute compensation result special circum fairness transparency remuneration decision stance clawback detail balanced mix long shortterm remuneration com ponent start restrict stock unit rsus nonvoting market competitiveness equity security vest period year introduce new remuneration component partially replac ing ssar option result well alignment roche longterm incentive value ssar award reduce balance award form rsus company incur additional cost result change aim strengthen align ment management interest interest roche shareholder group longterm success previous year remuneration report submit te separately advisory vote annual general meeting detail refer follow section remuneration report remuneration policy roche regularly review policy principle remuner ation framework employee policy aim motivate retain current employee attract tal ente new one help roche employee perform consistently high level remuneration policy design foster value creation reinforce culture performance innovation apply nonmanagerial employee manager ssar psp start restrict stock unit rsus remuneration component intend align management interest shareholder hold er nonvoting equity security participate manager additional incentive achieve continue value growth form longterm total shareholder return create value roche investor management benefit add value create investor manage ment penalise receive finance report note roche group consoli date financial statement relate party note financial statement roche holding ltd board executive remuneration board executive shareholding page remuneration report roche business report remuneration component december remuneration committee determine base pay bonus block nonvoting equity security bonus payable chairman board mem nes awards stocksettle stock appreciation right ber corporate executive committee respect ssar performance share plan psp start current reporting year base performance restrict stock unit rsus support fundamental aforementioned objective time remuner aim roche remuneration policy remuneration ation committee decide form bonus component link company financial perfor award cash payment andor block nonvoting equity mance commercial success align interest security roche employee shareholder c stocksettle stock appreciation right ssar explain principle govern remu stocksettle stock appreciation right ssar plan neration component report detail amount pay introduce january establish uniform system member board director component remuneration roche ssar entitle holder chairman board remuneration benefit financially increase value roche remuneration component pay member corpo nonvoting equity security grant date rate executive committee exercise date base pay ssar award allocate individually remuneration base pay cash payment determine position committee discretion base salary market datum lead global pharma ceutical company reflect individual ability experi restrict stock unit rsus ence performance time pay increase likewise start restrict stock unit rsus nonvoting link individual performance account prevail equity security vest period year e market condition company overall financial introduce new remuneration component partially replac situation ing ssar option result well alignment roche longterm incentive value ssar awards remuneration committee make review final reduce balance award decision base pay pay increase pay chair form rsus man board director member corporate executive committee remuneration e performance share plan member board member corporate executive committee member senior management currently individu b bonus al worldwide participate performance share plan bonus award individual contribution value cre psp establish period year ation normal job expectation mean base threeyear comparison total share incentive strive outstanding result create holder return tsr peer company new business opportunity bonus amount link overlapping performance cycle psp group divisional profit sale growth operating profit psp psp psp capital charge opac earning share ne close december growth pipeline achievement measurable qualitative individual functional performance objective term performance share plan conclusively competitive reason roche disclose individual determine board director annual basis act performance objective member corporate executive recommendation remuneration committee committee roche business report remuneration reportf ratio corporate executive committee variable remuneration element bonus ssar psp relative fix base pay end ssar criterion bonus start ssarsrsus psp individual target value assess max end ssar consideration performance start ssar base annual base pay competitor rsus measure january macroeconomic development year cycle relation value base pay minimum maximum relation value base pay cash payment value development value development block ne determine determined performance ne performance ne grant grant performance criterion group objective group individual contribution group performance divisional business remuneration tsr relation performance individual committee decision tsr performance objective consider profit discretion peer set sale growth opac operate profit capital charge earning share ne growth pipeline split group objective na b individual objective na remuneration board director bonuse salary chairman board corporate executive committee director member corporate executive committee year remuneration committee roche board set remuneration committee take account director set remuneration board member mem revision roche remuneration policy market comparison ber roche corporate executive committee base pay lead pharmaceutical company manage bonus ssar policy decision pension benefit ment change term performance share plan determine annually board director act recommenda remuneration vicechairmen board tion remuneration committee remuneration board member consist fix cash payment set committee track market datum salary lead discretion remuneration committee global pharmaceutical company report finding remuneration committee assist consultancy tower board information committee remit power watson track cash payment roche director procedure make remuneration decision market datum director pay lead global find bylaw roche board director pharmaceutical company major swiss compa outline precede section report ny principle govern specific remuneration component follow page provide detailed information remu neration pay member board director member corporate executive committee include comparison remuneration pay previous year httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm remuneration report roche business report remuneration member board director member board director award member board director receive fix share nonvoting equity security stocksettle stock remuneration cash payment show remuneration appreciation right ssar member board director table board activity basic remuneration board director william burns receive honoraria amount total remain unchanged remuneration mem dollar swiss franc serve mem ber board director remain unchanged ber board director chugai pharmaceutical co ltd arthur levinson receive payment consult work serve board genentech amounting list member position committee membership chairmanship dollar swiss franc remuneration member board director additional compensation additional special compensation remuneration committee memberschairs chf chf chf f b humer b high total remuner b high total remuner b high total remuner ation pay member ation pay member ation pay member board director board director board director b gehrig hoffmann p baschera j bell p bulcke w burns l j r de vink ch franz julius levinson oeri p r voser b weder di mauro total exception member presidium vicechairmen board member receive chf year committee serve chf year committee chair remuneration serve vicechairman board b high total remuneration pay member chairman board handover executive board director function ceo annual general meeting march chairman franz b humer member board receive additional ssar ne high total remuneration chairman programme psp rsu long enrol remuneration consist base salary bonus award roche ssar programme roche business report remuneration reporthigh total remuneration pay member board director chf chf chf salary bonus cash payment total pension fundsmgb roche connect total value detailed calculation remuneration annual report mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit include annual expense allowance chf payment tax consulting service chf chugai advisory mandate usd chf include employer contribution ahvivalv chf c stocksettle stock appreciation right ssar horst teltschik member board december franz b humer william burn director receive honoraria amount euro member board director hold swiss franc serve board ssar position member roche subsidiary germany corporate executive committee hold stocksettle stock appreciation right ssar show ssar table additional remuneration pay franz b humer ssar currently value remuneration member corporate executive committee general provision assign authority total remuneration pay board director decision corporate executive committee remuneration member board director receive remuneration committee board director remuneration totalling swiss franc outline page remuneration report swiss franc remuneration member corporate executive committee base pay chf annual salary annual salary annual salary schwan ayyoubi r diggelmann hippe g keller oday total member corporate executive committee prorate remuneration period april december include chf loss pension right grant employer contractual agreement remuneration report roche business report b bonus case severin schwan members cor remuneration committee board director deter porate executive committee receive bonus mine corporate executive committee member bonuse cash payment end april december base performance severin schwan receive bonus form roche agree objective nonvoting equity security block year roche nonvoting equity security grant end april bonus bonus bonus bonus total total total chf chf chf schwan cash payment block nonvoting equity security total bonus ayyoubi cash payment block nonvoting equity security total bonus r diggelmann cash payment block nonvoting equity security total bonus hippe cash payment block nonvoting equity security total bonus g keller cash payment block nonvoting equity security total bonus oday cash payment block nonvoting equity security total bonus total member corporate executive committee prorate remuneration period april december calculation value consideration reduction value block period year c stocksettle stock appreciation right ssar closing price roche ne grant date ssar ssar show ssar table vest year grant date vest ssar introduce roche january place stock exercise convert ne seven year grant option ssar entitle holder benefit financially date unexercised ssar lapse compensation increase value roche nonvoting equity security nes grant date exercise date fair value ssar calculate grant date strike price ssar term multiyear plan trinomial model american option trinomial roche business report remuneration reportmodel effective method valuation american number ssar strike price expiry date option consider possibility exercise option grant value ssar show ssar table time prior maturity call american option com number ssar calculate time pare european option allow exercise issue enter value table maturity date ssar grant strike price ne price december currently value recipient change roche future ne price improve information trinomial model american option refer boyle phelim p lattice framework option price state variable journal financial quantitative analysis volume issue mar wwwrochecom trinomialmodelpdf strike price table ssar stocksettle stock appreciation right ssar ssar ssar ssar value chf value chf value chf schwan ayyoubi r diggelmann hippe g keller oday total member corporate executive committee performance share plan psp ritie market price dividend yield ie total share member corporate executive committee holder return tsr calculate chf constant member senior management currently individu exchange rate reduce effect shortterm market fluc al worldwide participate performance share plan psp tuation security price average month october december prior start performance psp move overlap threeyear performance cycle month october december cycle new cycle beginning year end cycle cycle progress psp psp psp previous year psp roche security perform well average peer psp psp psp set roche tsr increase cycle close december award tar board director elect increase nes award get nes maximum award double original level reserve target number ne accord psp plan require provision plan number nonvoting roche security perform well equity security nes reserve partici peer set event investment roche pant cycle number security actually award security underperform average return deliver depend extent investment peer company few ne award roche security share ne outperform average return investment security issue peer set comparator company comparison base secu footnote remuneration report roche business report performance share plan psp total estimate value psp award award ne ne ne target award award award target number target number number ne ne psp ne psp psp psp psp psp value chf value chf value chf value chf schwan ayyoubi r diggelmann hippe g keller oday total member corporate executive committee total estimate value psp originally target ne award psp estimate value calculate yearend price december chf nonvoting equity security ne base number ne originally target subject change number value ne awardable plan december december respectively spread relevant period time ie year board director vote actual allocation originally target ne december december respectively accord tsr achieve ne reserve plan member e indirect benefit corporate executive committee show table employer contribution social security board director decide actual level ne scheme pension plan groupwide employee stock cash equivalent award cycle purchase plan roche connect respect member close financial year corporate executive committee show indirect respectively aim psp provide incentive benefit table participant achieve steady value growth roche connect voluntary stock purchase plan offering end psp cycle base employee opportunity buy roche nonvoting equity month move average distribute dividend total security ne equal annual billion swiss franc billion swiss franc salary discount ne purchase plan billion swiss franc billion swiss subject hold period year switzerland franc tsr roche security ne share rank th compare peer set company operat ing industry accord term plan participant receive originally tar get ne table detail roche business report remuneration reportindirect benefit payment pension fundsmgb ahvivalv roche connect tax consulting service insurance chf chf chf chf schwan ayyoubi r diggelmann hippe g keller oday total mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit ahvivalv swiss social security programme provide retirement disability unemployment benefit f remuneration emolument loan ahvivalv swiss franc payment member corporate executive committee additionally include corporate executive committee mem receive annual expense allowance swiss franc ber total remuneration swiss franc roland diggelmann receive prorate unvested ssar target psp ne award lapse swiss franc total swiss franc compensation silvia ayyoubi daniel oday receive nonrecurre spe pension total swiss franc pay cial payment swiss franc year corporate executive committee member service company maximum regular period notice member cor contractual obligation roche pay daniel porate executive committee month contractually oday alan hippe swiss francs swiss agree severance payment exceed payment franc respectively children school cost notice period previously include employment con tract eliminate lapse respectively expense total swiss franc pay roland future severance payment long agree diggelmann position change control clause employment contract time provision severin pascal soriot coo division roche pharmaceutical schwan alan hippe receive supplementary death take new responsibility outside company start disability benefit companyfunde retirement benefit ing september receive follow payment base event early retirement insurance benefit exist contractual obligation salary prorate fully fund single payment payment swiss franc bonus prorate cash pay include total remuneration swiss franc ment swiss franc payable april pay corporate executive committee previous year form roche nonvoting equity security block swiss franc year amount swiss franc ne calculate base market value average month g high total remuneration pay member grant begin january corporate executive committee expense allowance prorate swiss franc payment severin schwan ceo member corporate tax consulting service swiss franc employer con executive committee high total remuneration tribution pension fund etc swiss franc remuneration report roche business report high total remuneration pay member corporate executive committee chf chf chf salary bonus cash payment block nonvoting equity security total ssar grant value accord trinomial model american option pension fundsmgb insurance roche connect estimate value target award ne accord performance share plan awardsvalue nes total total value calculation value consideration reduction value block period year reduce market value detailed calculation remuneration annual report trinomial model american option value describe remuneration member corporate executive committee c stocksettle stock appreciation right ssar mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit basic rule detailed calculation remuneration member corporate executive committee performance share plan footnote respectively include annual expense allowance chf payment tax consulting service chf exclude employer contribution ahvivalv payment h total remuneration pay member table show impact effective corporate executive committee remuneration current member corporate execu member corporate executive committee tive committee past seven year receive remuneration totalling swiss franc swiss franc include ahvivalv movement price nonvoting equity security strike price ssar grant year indi additional remuneration mention cat table nonvoting equity payment pay current member cor security price december cur porate executive committee rently worthless table show originally disclose val ue currently outofthemoney ssar add compensation pay member ot cor alignment interest manager porate executive committee shareholdersholder nonvoting equity security ssar psp remuneration component intend performance target meet psp programme align management interest shareholder end holder nonvoting equity security participat allocation target nonvoting equity security ing manager additional incentive achieve continue table contain remuneration equivalent value growth form longterm total shareholder return nonvoting equity security allocate psp create value roche investor management benefit value originally credit member corporate add value create investor manage executive committee publish accordingly remu ment penalise receive neration report roche business report remuneration reportssar money december psp participation programme remuneration distribute ssar psp money disbursementissuance december value grant psp psp psp psp total total total chf chf chf schwan ayyoubi g keller oday p soriot total psp value calculation base corresponding base pay alan hippe roland diggelmann list table repeat willful failure perform duty roche employee roche corporate reasonably assign roche executive committee member period question violation law public regulation commission crime gross negligence willful misconduct employment clawback engage conduct bring disgrace disrepute roche addition applicable statutory provision roche long andor subsidiary term incentive plan include option partially reclaim dis violation roche directive guideline relate tributed compensation result special circumstance business conduct clawback accord regulation psp programme origi employee voluntarily serve notice termination nally target award ne shall lapse employment ssar unvested date termi compensation notice termination employment nation employment lapse immediately compen give reason redundancy disability retire sation ment termination employment result miscon duct ssar grant outstanding vest guideline security holding unvested shall lapse immediately compensation board director decide ceo accord ssar plan rule misconduct cec member acquire share andor nes equivalent participant include inter alia annual base salary ceo annual base salary activity lead disciplinary action respectively end retain holding long serve cec type security equivalence ceo share andor nes x annual base salary member corporate executive committee share andor nes x annual base salary remuneration report roche business report security holding solidate financial statement relate party director andr hoffmann andreas oeri member note financial statement roche holding ltd founder family closely associate significant shareholder addition belong shareholder group pool voting right december member board director end group hold share person closely associate member issue share detailed information group cec person closely associate hold share find finance report note roche group con nes show table security holding december close relative share ne security holding number number numbertype number board director f b humer ssar b gehrig hoffmann ubs longshort certificate link roche bearer share roche nonvoting equity securities valor isin ch expiry date march p baschera j bell p bulcke w burns ssar l j r de vink american depository receipts adr rhhby isin ch franz julius levinson oeri ubs longshort certificate link roche bearer share roche nonvoting equity securities valor isin ch expiry date march p r voser b weder di mauro total corporate executive committee schwan ssar ayyoubi ssar r diggelmann ssarsoption hippe ssar g keller share ssar oday ssar total share share hold shareholder group pool voting right list roche business report remuneration report ssar number ssar hold current member corporate executive committee december total corporate executive committee schwan ayyoubi r diggelmann hippe g keller oday total corporate executive committee member f b humer w burn strike price chf market price ne december chf expiry date grant value ssar chf trinomial model american option value accord correspond annual report position option hold option show table issue roche employee stock option option entitle holder purchase roche nonvoting equity security ne term multiyear option plan strike price option show closing price roche ne grant date option show nontradable onethird option subject vest period year onethird vest period year onethird vest period year unvested option lapse compensation employment terminate voluntarily reason retirement vest option exercise limited period time franz b humer receive additional ssar franz b humer receive ssar member corporate executive committee william burns receive additional ssar william burn receive ssar member corporate executive committee remuneration report roche business report independent assurance report corporate governance sustainability committee criterion roche holding ag basel roche roche group internal corporate responsibility report guideline base responsible care health safety perform assurance procedure provide limited environmental protection report guideline publish assurance follow aspect corporate european chemical industry council cefic responsibility report roche sustainability report guideline g publish global reporting initiative gri subject matter roche group internal corporate reporting manual datum information disclose corporate responsibility version sustainability report economic perfor report roche consolidated subsidiary exclud mance datum e chugai pharmaceutical co ltd business year define guideline people donation end december follow aspect sponsorship key figure gather collate indicate level assurance aggregate internally management reporting process respect corporate responsibility report preparation responsibility methodology people donation sponsorship key figure accuracy completeness corporate responsibility control environment relation datum aggre indicator subject inherent limitation give nature gation key figure limited assurance method determine calculate estimate key figure include scope co emission datum assurance report read con business travel table graph page nection roche internal guideline definition pro select people key figure disclose cedure report corporate responsibility page roche business report formance future orientate data information limited assurance assurance scope provide assurance consolidated datum information roche group statement scope level relation donation sponsorship exclude health care professional hcp related activity roche corporate governance sustainability commit limited assurance tee responsible preparation presen tation select subject matter accordance report criterion responsibility comprises arrange ment implementation maintenance adequate record internal control design support sustain ability reporting process responsibility form independent conclusion base limited assurance procedure come attention indicate subject matter state material respect accordance report ing criterion business year end december conduct engagement accordance international standard assurance engagement isae issue international auditing assurance standard board roche business report independent assurance reportmain assurance procedure conclusion assurance procedure include follow work reference identify subject matter information evaluation application roche group guideline base work perform come review application roche group internal cor attention cause believe porate responsibility report donation sponsor roche group internal corporate responsibility report ship guideline guideline base gri g sustainability reporting site visit guideline cefic guideline apply visit select site roche pharma diagnostic material respect accordance report cri division germany morocco south africa united arab teria emirates singapore usa selection base internal reporting process collect aggregate quantitative qualitative criterion interview personnel people donation sponsorship datum func responsible internal corporate responsibility report tioning design provide appropriate data collection site visit roche basis disclosure material respect accordance group level determine understand application reporting criterion roche internal corporate responsibility guideline corporate responsibility information mention assessment key figure subject matter disclose corporate responsibil perform test sample basis evidence support ity report roche business report state select people donation sponsorship key fig material respect accordance report cri ure roche accident rate energy consumption co emis teria sion relate energy consumption release halogenate hydrocarbon headcountfte datum staff statistic labor practice information contribution philanthropic organi zurich january zations patient organization health institution public pol icy body concern completeness accuracy adequacy pricewaterhousecoopers ag consistency review documentation analysis relevant policy basic principle review relevant documentation sample basis include roche group corporate responsibility policy christophe bourgoin stephan hirschi management report structure documentation assessment process data consolidation review appropriateness management ofand reporting process corporate responsibility key datum assess consolidation process datum roche group level independent assurance report roche business report publish cautionary statement forwardlooke f hoffmannla roche ltd statement basel switzerland annual report contain certain forwardlooking statement tel forwardlooke statement identify word believe expect anticipate project intend seek fax estimate future imilar expression discussion thing strategy goal plan intention factor medium office cause actual result differ materially future group communication reflect forwardlooke statement contain annual basel switzerland report price product initiative competi tel tor legislative regulatory development economic con fax dition delay inability obtain regulatory approval bring ing product market fluctuation currency exchange rate general financial market condition uncertaintie dis investor relation covery development marketing new product new use basel switzerland exist product include limitation negative result clini tel cal trial research project unexpected effect pipeline fax market product increase government pricing pressure interruption production loss inability obtain adequate website protection intellectual property right litigation loss key wwwrochecom executive employee adverse publicity news coverage corporate sustainability committee statement earning share growth profit tel forecast interpret mean roche earning email corporatesustainabilityrochecom earning share subsequent period nece sarily match exceed historical publish earning earning order publication share roche tel fax trademark mention enjoy legal protection email baselwebmasterrochecom link party page provide convenience express opinion content thirdparty page annual general meeting expressly disclaim liability thirdparty information march use roche annual report publish german english print nonchlorine bleach fsccertified paper roche annual report issue f hoffmannla roche ltd basel group communication